

Glenda Halliday

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7383115/publications.pdf>

Version: 2024-02-01

700
papers

72,038
citations

1027

117
h-index

1142

237
g-index

728
all docs

728
docs citations

728
times ranked

51432
citing authors

#	ARTICLE	IF	CITATIONS
1	Parkinsonism and cerebrovascular disease. <i>Journal of the Neurological Sciences</i> , 2022, 433, 120011.	0.3	11
2	Chemoselective Bioconjugation of Amyloidogenic Protein Antigens to PEGylated Microspheres Enables Detection of Î±-Synuclein Autoantibodies in Human Plasma. <i>Bioconjugate Chemistry</i> , 2022, , .	1.8	0
3	Limbic thalamus atrophy is associated with visual hallucinations in Lewy body disorders. <i>Neurobiology of Aging</i> , 2022, 112, 122-128.	1.5	3
4	Identifying gene expression profiles associated with neurogenesis and inflammation in the human subependymal zone from development through aging. <i>Scientific Reports</i> , 2022, 12, 40.	1.6	8
5	Cerebellar integrity and contributions to cognition in C9orf72-mediated frontotemporal dementia. <i>Cortex</i> , 2022, 149, 73-84.	1.1	2
6	Prion-like Î±-synuclein pathology in the brain of infants with Krabbe disease. <i>Brain</i> , 2022, 145, 1257-1263.	3.7	9
7	Narrow doorways alter brain connectivity and step patterns in isolated REM sleep behaviour disorder. <i>NeuroImage: Clinical</i> , 2022, 33, 102958.	1.4	3
8	Examining the presence and nature of delusions in Alzheimerâ€™s disease and frontotemporal dementia syndromes. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	1.3	4
9	Biomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosis. <i>Brain</i> , 2022, 145, 1598-1609.	3.7	17
10	Dynamic network impairments underlie cognitive fluctuations in Lewy body dementia. <i>Npj Parkinson's Disease</i> , 2022, 8, 16.	2.5	4
11	Comprehensive genetic diagnosis of tandem repeat expansion disorders with programmable targeted nanopore sequencing. <i>Science Advances</i> , 2022, 8, eabm5386.	4.7	68
12	Effect of LRRK2 protein and activity on stimulated cytokines in human monocytes and macrophages. <i>Npj Parkinson's Disease</i> , 2022, 8, 34.	2.5	18
13	Schizotypal traits across the amyotrophic lateral sclerosisâ€™frontotemporal dementia spectrum: pathomechanistic insights. <i>Journal of Neurology</i> , 2022, , 1.	1.8	0
14	Thalamic and Cerebellar Regional Involvement across the ALSâ€™FTD Spectrum and the Effect of C9orf72. <i>Brain Sciences</i> , 2022, 12, 336.	1.1	6
15	Immune responses in the Parkinson's disease brain. <i>Neurobiology of Disease</i> , 2022, 168, 105700.	2.1	30
16	The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. <i>Movement Disorders</i> , 2022, 37, 1131-1148.	2.2	222
17	Sex-specific lipid dysregulation in the <i>Abca7</i> knockout mouse brain. <i>Brain Communications</i> , 2022, 4, .	1.5	4
18	Altered SOD1 maturation and post-translational modification in amyotrophic lateral sclerosis spinal cord. <i>Brain</i> , 2022, 145, 3108-3130.	3.7	25

#	ARTICLE	IF	CITATIONS
19	Overlap between Central and Peripheral Transcriptomes in Parkinson's Disease but Not Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5200.	1.8	5
20	Lipid pathway dysfunction is prevalent in patients with Parkinson's disease. <i>Brain</i> , 2022, 145, 3472-3487.	3.7	25
21	A small molecule toll-like receptor antagonist rescues α -synuclein fibril pathology. <i>Journal of Biological Chemistry</i> , 2022, 298, 102260.	1.6	6
22	Utility of the Addenbrooke's Cognitive Examination III online calculator to differentiate the primary progressive aphasia variants. <i>Brain Communications</i> , 2022, 4, .	1.5	6
23	TDP-43 proteinopathies: a new wave of neurodegenerative diseases. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 86-95.	0.9	174
24	Evaluating a novel behavioral paradigm for visual hallucinations in Dementia with Lewy bodies. <i>Aging Brain</i> , 2021, 1, 100011.	0.7	2
25	Clinical and Biological Correlates of White Matter Hyperintensities in Patients With Behavioral-Variant Frontotemporal Dementia and Alzheimer Disease. <i>Neurology</i> , 2021, 96, e1743-e1754.	1.5	24
26	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. <i>Nature Genetics</i> , 2021, 53, 294-303.	9.4	198
27	Meta-analysis of genome-wide DNA methylation identifies shared associations across neurodegenerative disorders. <i>Genome Biology</i> , 2021, 22, 90.	3.8	49
28	Globular glial tauopathy with a mutation in MAPT and unusual TDP-43 proteinopathy in a patient with behavioural-variant frontotemporal dementia. <i>Acta Neuropathologica</i> , 2021, 141, 791-794.	3.9	4
29	Defining early changes in Alzheimer's disease from RNA sequencing of brain regions differentially affected by pathology. <i>Scientific Reports</i> , 2021, 11, 4865.	1.6	23
30	Parkinson's Disease Subtypes: Critical Appraisal and Recommendations. <i>Journal of Parkinson's Disease</i> , 2021, 11, 395-404.	1.5	56
31	Loss of the metabolism and sleep regulating neuronal populations expressing orexin and oxytocin in the hypothalamus in amyotrophic lateral sclerosis. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 979-989.	1.8	31
32	Comparison of Locus Coeruleus Pathology with Nigral and Forebrain Pathology in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2085-2093.	2.2	23
33	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. <i>Biological Psychiatry</i> , 2021, 89, 825-835.	0.7	10
34	Prodromal neuroinvasion of pathological α -synuclein in brainstem reticular nuclei and white matter lesions in a model of α -synucleinopathy. <i>Brain Communications</i> , 2021, 3, fcab104.	1.5	7
35	Coexisting Lewy body disease and clinical parkinsonism in amyotrophic lateral sclerosis. <i>European Journal of Neurology</i> , 2021, 28, 2192-2199.	1.7	6
36	Anterior-posterior electrophysiological activity characterizes Parkinsonian visual misperceptions. <i>Neurology and Clinical Neuroscience</i> , 2021, 9, 312-318.	0.2	2

#	ARTICLE	IF	CITATIONS
37	Reduced adult neurogenesis is associated with increased macrophages in the subependymal zone in schizophrenia. <i>Molecular Psychiatry</i> , 2021, 26, 6880-6895.	4.1	20
38	Neural mechanisms of psychosis vulnerability and perceptual abnormalities in the ALS&FTD spectrum. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1576-1591.	1.7	11
39	Comparison of Different Platform Immunoassays for the Measurement of Plasma Alpha-Synuclein in Parkinson&TM's Disease Patients. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1761-1772.	1.5	15
40	Alpha-synuclein research: defining strategic moves in the battle against Parkinson&TM's disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 65.	2.5	74
41	PARK Genes Link Mitochondrial Dysfunction and Alpha-Synuclein Pathology in Sporadic Parkinson&TM's Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 612476.	1.8	32
42	Parkinson disease-associated cognitive impairment. <i>Nature Reviews Disease Primers</i> , 2021, 7, 47.	18.1	391
43	Native Separation and Metallation Analysis of SOD1 Protein from the Human Central Nervous System: a Methodological Workflow. <i>Analytical Chemistry</i> , 2021, 93, 11108-11115.	3.2	6
44	Alpha-synuclein activates the classical complement pathway and mediates complement-dependent cell toxicity. <i>Journal of Neuroinflammation</i> , 2021, 18, 177.	3.1	18
45	Glucocerebrosidase Activity is Reduced in Cryopreserved Parkinson&TM's Disease Patient Monocytes and Inversely Correlates with Motor Severity. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1157-1165.	1.5	11
46	Progression of Clinical Features in Lewy Body Dementia Can Be Detected Over 6 Months. <i>Neurology</i> , 2021, 97, e1031-e1040.	1.5	11
47	Early white matter pathology in the fornix of the limbic system in Huntington disease. <i>Acta Neuropathologica</i> , 2021, 142, 791-806.	3.9	13
48	Protein phosphatase 2A holoenzymes regulate leucine-rich repeat kinase 2 phosphorylation and accumulation. <i>Neurobiology of Disease</i> , 2021, 157, 105426.	2.1	7
49	Glycoprotein Pathways Altered in Frontotemporal Dementia With Autoimmune Disease. <i>Frontiers in Immunology</i> , 2021, 12, 736260.	2.2	2
50	Amyotrophic lateral sclerosis features predict TDP-43 pathology in frontotemporal lobar degeneration. <i>Neurobiology of Aging</i> , 2021, 107, 11-20.	1.5	1
51	Hypothalamic symptoms of frontotemporal dementia disorders. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2021, 182, 269-280.	1.0	9
52	Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study. <i>Acta Neuropathologica</i> , 2021, 141, 159-172.	3.9	107
53	The aging brain and brain banking. , 2021, , 103-112.		0
54	Differences in Sex Distribution Between Genetic and Sporadic Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 1153-1161.	1.2	11

#	ARTICLE	IF	CITATIONS
55	Tackling clinical heterogeneity across the amyotrophic lateral sclerosis–frontotemporal dementia spectrum using a transdiagnostic approach. <i>Brain Communications</i> , 2021, 3, fcab257.	1.5	16
56	Increased VLCFA-lipids and ELOVL4 underlie neurodegeneration in frontotemporal dementia. <i>Scientific Reports</i> , 2021, 11, 21348.	1.6	11
57	Factors That Influence Non-Motor Impairment Across the ALS-FTD Spectrum: Impact of Phenotype, Sex, Age, Onset and Disease Stage. <i>Frontiers in Neurology</i> , 2021, 12, 743688.	1.1	6
58	Pathological manifestation of human endogenous retrovirus K in frontotemporal dementia. <i>Communications Medicine</i> , 2021, 1, .	1.9	14
59	Presence of co-pathology in sporadic early-onset Alzheimer disease versus dominantly inherited Alzheimer disease. <i>Alzheimer's and Dementia</i> , 2021, 17, e055045.	0.4	0
60	Cognitive fluctuations in Lewy body dementia: towards a pathophysiological framework. <i>Brain</i> , 2020, 143, 31-46.	3.7	53
61	Intracellular and secreted forms of clusterin are elevated early in Alzheimer's disease and associate with both A β and tau pathology. <i>Neurobiology of Aging</i> , 2020, 89, 129-131.	1.5	19
62	Evaluating the Sustained Attention Response Task to Quantify Cognitive Fluctuations in Dementia With Lewy Bodies. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2020, 33, 333-339.	1.2	7
63	Assessing the role of nocturnal core body temperature dysregulation as a biomarker of neurodegeneration. <i>Journal of Sleep Research</i> , 2020, 29, e12939.	1.7	19
64	Clinical features of Lewy body dementia: insights into diagnosis and pathophysiology. <i>Journal of Neurology</i> , 2020, 267, 380-389.	1.8	17
65	Are mutations in <i>MAPT</i> associated with GGT type III?. <i>Neuropathology and Applied Neurobiology</i> , 2020, 46, 406-409.	1.8	4
66	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 145-156.	4.9	175
67	LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation. <i>Neurobiology of Disease</i> , 2020, 144, 105049.	2.1	10
68	The complex relationship between genotype, pathology and phenotype in familial dementia. <i>Neurobiology of Disease</i> , 2020, 145, 105082.	2.1	6
69	Neuronal intranuclear inclusion disease is genetically heterogeneous. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1716-1725.	1.7	38
70	Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. <i>Scientific Reports</i> , 2020, 10, 12184.	1.6	4
71	Author response: The underacknowledged PPA-ALS: A unique clinicopathologic subtype with strong heritability. <i>Neurology</i> , 2020, 94, 283-283.	1.5	0
72	Altered serum protein levels in frontotemporal dementia and amyotrophic lateral sclerosis indicate calcium and immunity dysregulation. <i>Scientific Reports</i> , 2020, 10, 13741.	1.6	26

#	ARTICLE	IF	CITATIONS
73	A Practical Approach to Differentiate the Frontotemporal Tauopathy Subtypes. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 1122-1126.	0.9	1
74	Circular RNAs: The Brain Transcriptome Comes Full Circle. <i>Trends in Neurosciences</i> , 2020, 43, 752-766.	4.2	51
75	Antihypertensive medications ameliorate Alzheimer's disease pathology by slowing its propagation. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12060.	1.8	12
76	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the <sc>Movement Disorder Society</sc> Multiple System Atrophy Study Group. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 750-762.	0.8	31
77	Alzheimer's amyloid β and tau protein accumulation is associated with decreased expression of the LDL receptor-associated protein in human brain tissue. <i>Brain and Behavior</i> , 2020, 10, e01672.	1.0	6
78	Transcriptional profiling of multiple system atrophy cerebellar tissue highlights differences between the parkinsonian and cerebellar sub-types of the disease. <i>Acta Neuropathologica Communications</i> , 2020, 8, 76.	2.4	20
79	The Neural Signature of Impaired <sc>Dual-Tasking</sc> in Idiopathic Rapid Eye Movement Sleep Behavior Disorder Patients. <i>Movement Disorders</i> , 2020, 35, 1596-1606.	2.2	12
80	CYLD is a causative gene for frontotemporal dementia " amyotrophic lateral sclerosis. <i>Brain</i> , 2020, 143, 783-799.	3.7	62
81	Analysis of DNA methylation associates the cystine-glutamate antiporter SLC7A11 with risk of Parkinson's disease. <i>Nature Communications</i> , 2020, 11, 1238.	5.8	85
82	Genetic and immunopathological analysis of CHCHD10 in Australian amyotrophic lateral sclerosis and frontotemporal dementia and transgenic TDP-43 mice. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 162-171.	0.9	8
83	Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 22.	3.0	74
84	Accelerated loss of hypoxia response in zebrafish with familial Alzheimer's disease-like mutation of presenilin 1. <i>Human Molecular Genetics</i> , 2020, 29, 2379-2394.	1.4	12
85	Uncovering pathophysiological changes in frontotemporal dementia using serum lipids. <i>Scientific Reports</i> , 2020, 10, 3640.	1.6	39
86	Invited Reply to: "Instrumental Analysis of Gait Abnormalities in Idiopathic Rapid Eye Movement Sleep Behavior Disorder" • <i>Movement Disorders</i> , 2020, 35, 195-196.	2.2	0
87	Dementia in long-term Parkinson's disease patients: a multicentre retrospective study. <i>Npj Parkinson's Disease</i> , 2020, 6, 2.	2.5	32
88	Fulminant corticobasal degeneration: a distinct variant with predominant neuronal tau aggregates. <i>Acta Neuropathologica</i> , 2020, 139, 717-734.	3.9	15
89	Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. <i>Acta Neuropathologica Communications</i> , 2020, 8, 5.	2.4	27
90	ESHRD: deconvolution of brain homogenate RNA expression data to identify cell-type-specific alterations in Alzheimer's disease. <i>Aging</i> , 2020, 12, 4124-4162.	1.4	4

#	ARTICLE	IF	CITATIONS
91	Neglected cytotoxic T cell invasion of the brain: how specific for Parkinson's disease?. <i>Brain</i> , 2020, 143, 3518-3521.	3.7	3
92	Flow Cytometry Measurement of Glucocerebrosidase Activity in Human Monocytes. <i>Bio-protocol</i> , 2020, 10, e3572.	0.2	2
93	<i>SIRT1</i> is increased in affected brain regions and hypothalamic metabolic pathways are altered in Huntington disease. <i>Neuropathology and Applied Neurobiology</i> , 2019, 45, 361-379.	1.8	31
94	Alpha-synuclein: prion or prion-like?. <i>Acta Neuropathologica</i> , 2019, 138, 509-514.	3.9	14
95	CNS cell type-specific gene profiling of P301S tau transgenic mice identifies genes dysregulated by progressive tau accumulation. <i>Journal of Biological Chemistry</i> , 2019, 294, 14149-14162.	1.6	10
96	Reply: LATE to the PART-y. <i>Brain</i> , 2019, 142, e48-e48.	3.7	11
97	Autophagy activation promotes clearance of α -synuclein inclusions in fibril-seeded human neural cells. <i>Journal of Biological Chemistry</i> , 2019, 294, 14241-14256.	1.6	76
98	Arylsulfatase A, a genetic modifier of Parkinson's disease, is an α -synuclein chaperone. <i>Brain</i> , 2019, 142, 2845-2859.	3.7	44
99	Neuroinflammation in frontotemporal dementia. <i>Nature Reviews Neurology</i> , 2019, 15, 540-555.	4.9	159
100	Recent Developments in TSPO PET Imaging as A Biomarker of Neuroinflammation in Neurodegenerative Disorders. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3161.	1.8	173
101	Parkinson's progression prediction using machine learning and serum cytokines. <i>Npj Parkinson's Disease</i> , 2019, 5, 14.	2.5	63
102	Cross-examining candidate genes implicated in multiple system atrophy. <i>Acta Neuropathologica Communications</i> , 2019, 7, 117.	2.4	22
103	Chronic traumatic encephalopathy in two former Australian National Rugby League players. <i>Acta Neuropathologica Communications</i> , 2019, 7, 97.	2.4	28
104	Expression of tyrosine hydroxylase isoforms and phosphorylation at serine 40 in the human nigrostriatal system in Parkinson's disease. <i>Neurobiology of Disease</i> , 2019, 130, 104524.	2.1	20
105	TDP-43 levels in the brain tissue of ALS cases with and without C9ORF72 or ATXN2 gene expansions. <i>Neurology</i> , 2019, 93, e1748-e1755.	1.5	20
106	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. <i>Lancet Neurology</i> , The, 2019, 18, 1091-1102.	4.9	1,414
107	Improved precision of epigenetic clock estimates across tissues and its implication for biological ageing. <i>Genome Medicine</i> , 2019, 11, 54.	3.6	191
108	Letter to the Editor. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 975-977.	0.9	3

#	ARTICLE	IF	CITATIONS
109	Multiple system atrophy prions retain strain specificity after serial propagation in two different Tg(SNCA ^{A53T}) mouse lines. <i>Acta Neuropathologica</i> , 2019, 137, 437-454.	3.9	58
110	Eating peptides: biomarkers of neurodegeneration in amyotrophic lateral sclerosis and frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 486-495.	1.7	40
111	Cellular and regional vulnerability in frontotemporal tauopathies. <i>Acta Neuropathologica</i> , 2019, 138, 705-727.	3.9	49
112	Subtle gait and balance impairments occur in idiopathic rapid eye movement sleep behavior disorder. <i>Movement Disorders</i> , 2019, 34, 1374-1380.	2.2	36
113	Increased Tau Phosphorylation in Motor Neurons From Clinically Pure Sporadic Amyotrophic Lateral Sclerosis Patients. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 605-614.	0.9	19
114	Targeted, High-Resolution RNA Sequencing of Non-coding Genomic Regions Associated With Neuropsychiatric Functions. <i>Frontiers in Genetics</i> , 2019, 10, 309.	1.1	28
115	Von Economo Neurons in Behavioral Variant Frontotemporal Dementia with Underlying Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 963-967.	1.2	10
116	Coexisting Lewy body disease and clinical parkinsonism in frontotemporal lobar degeneration. <i>Neurology</i> , 2019, 92, e2472-e2482.	1.5	16
117	Temporal evolution of microglia and α -synuclein accumulation following foetal grafting in Parkinson's disease. <i>Brain</i> , 2019, 142, 1690-1700.	3.7	75
118	α 2 and tau prion-like activities decline with longevity in the Alzheimer's disease human brain. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	96
119	Impaired Color Discrimination – A Specific Marker of Hallucinations in Lewy Body Disorders. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2019, 32, 257-264.	1.2	11
120	Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. <i>Brain</i> , 2019, 142, 1503-1527.	3.7	873
121	Levels of glial cell line-derived neurotrophic factor are decreased, but fibroblast growth factor 2 and cerebral dopamine neurotrophic factor are increased in the hippocampus in Parkinson's disease. <i>Brain Pathology</i> , 2019, 29, 813-825.	2.1	24
122	A critique of the second consensus criteria for multiple system atrophy. <i>Movement Disorders</i> , 2019, 34, 975-984.	2.2	73
123	Dopamine depletion alters macroscopic network dynamics in Parkinson's disease. <i>Brain</i> , 2019, 142, 1024-1034.	3.7	50
124	The C9orf72 hexanucleotide repeat expansion presents a challenge for testing laboratories and genetic counseling. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2019, 20, 310-316.	1.1	16
125	Heritability and genetic variance of dementia with Lewy bodies. <i>Neurobiology of Disease</i> , 2019, 127, 492-501.	2.1	29
126	Genome-wide analyses as part of the international FTLT-DTP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLT. <i>Acta Neuropathologica</i> , 2019, 137, 879-899.	3.9	90

#	ARTICLE	IF	CITATIONS
127	The underacknowledged PPA-ALS. <i>Neurology</i> , 2019, 92, e1354-e1366.	1.5	29
128	Heritability in frontotemporal tauopathies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 115-124.	1.2	17
129	060â€...Impaired color discrimination is associated with hallucinations in dementia with lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, A19.3-A20.	0.9	0
130	001â€...Altered interval timing as a novel marker of cognitive fluctuations in lewy body dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, A1.1-A1.	0.9	2
131	037â€...Frontotemporal dementia or frontal variant alzheimerâ€™s disease? A case series. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, A13.1-A13.	0.9	0
132	093â€...How to diagnose lewy body dementia? Prevalence and underlying relationship between clinical and neuropsychological features of DLB. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, A30.1-A30.	0.9	0
133	095â€...Predicting parkinsonâ€™s and dementia with lewy bodies (pre-D) research study â€“ a sydney-based longitudinal biobanking program. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, A30.3-A31.	0.9	0
134	Reductions in COQ2 Expression Relate to Reduced ATP Levels in Multiple System Atrophy Brain. <i>Frontiers in Neuroscience</i> , 2019, 13, 1187.	1.4	11
135	Structural heterogeneity of Î±-synuclein fibrils amplified from patient brain extracts. <i>Nature Communications</i> , 2019, 10, 5535.	5.8	153
136	Secernin-1 is a novel phosphorylated tau binding protein that accumulates in Alzheimerâ€™s disease and not in other tauopathies. <i>Acta Neuropathologica Communications</i> , 2019, 7, 195.	2.4	18
137	LRRK2â€mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients. <i>Movement Disorders</i> , 2019, 34, 406-415.	2.2	83
138	Predictors of survival and progression in behavioural variant frontotemporal dementia. <i>European Journal of Neurology</i> , 2019, 26, 774-779.	1.7	22
139	Apolipoprotein D Upregulation in Alzheimerâ€™s Disease but Not Frontotemporal Dementia. <i>Journal of Molecular Neuroscience</i> , 2019, 67, 125-132.	1.1	29
140	Brain Banking for Research into Neurodegenerative Disorders and Ageing. <i>Neuroscience Bulletin</i> , 2019, 35, 283-288.	1.5	14
141	Gutâ€brain axis and the spread of Î±-synuclein pathology: Vagal highway or dead end?. <i>Movement Disorders</i> , 2019, 34, 307-316.	2.2	144
142	Molecular Pathogenesis of the Tauopathies. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2019, 14, 239-261.	9.6	161
143	A comprehensive screening of copy number variability in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2019, 75, 223.e1-223.e10.	1.5	13
144	Region- and Cell-specific Aneuploidy in Brain Aging and Neurodegeneration. <i>Neuroscience</i> , 2018, 374, 326-334.	1.1	28

#	ARTICLE	IF	CITATIONS
145	Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers. <i>Brain</i> , 2018, 141, 486-495.	3.7	36
146	Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies. <i>Brain</i> , 2018, 141, 521-534.	3.7	114
147	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. <i>Lancet Neurology</i> , The, 2018, 17, 548-558.	4.9	97
148	Alpha-synuclein aggregates activate calcium pump SERCA leading to calcium dysregulation. <i>EMBO Reports</i> , 2018, 19, .	2.0	88
149	Selective Spatiotemporal Vulnerability of Central Nervous System Neurons to Pathologic TAR DNA-Binding Protein 43 in Aged Transgenic Mice. <i>American Journal of Pathology</i> , 2018, 188, 1447-1456.	1.9	8
150	Physiological changes in neurodegeneration – mechanistic insights and clinical utility. <i>Nature Reviews Neurology</i> , 2018, 14, 259-271.	4.9	72
151	Accumulation of dysfunctional SOD1 protein in Parkinson’s disease is not associated with mutations in the SOD1 gene. <i>Acta Neuropathologica</i> , 2018, 135, 155-156.	3.9	23
152	MSA prions exhibit remarkable stability and resistance to inactivation. <i>Acta Neuropathologica</i> , 2018, 135, 49-63.	3.9	70
153	Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. <i>Neurology</i> , 2018, 90, 74-82.	1.5	23
154	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. <i>Lancet Neurology</i> , The, 2018, 17, 64-74.	4.9	195
155	Multiple neuronal pathologies are common in young patients with pathologically proven Frontotemporal lobar degeneration. <i>Neuropathology and Applied Neurobiology</i> , 2018, 44, 522-532.	1.8	9
156	P1405: VISUAL ASSESSMENT OF β -AMYLOID PET SCAN IS IMPROVED BY CAPAIBL. <i>Alzheimer's and Dementia</i> , 2018, 14, P459.	0.4	0
157	A52...SIRT1 is increased in affected brain regions in huntington disease impacting hypothalamic metabolic pathways. , 2018, , .		0
158	O13...Lipid metabolism and body composition in frontotemporal dementia-amyotrophic lateral sclerosis spectrum: effect on survival and disease progression. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A6.3-A7.	0.9	0
159	Altered High Density Lipoprotein Composition in Behavioral Variant Frontotemporal Dementia. <i>Frontiers in Neuroscience</i> , 2018, 12, 847.	1.4	16
160	110...Atrophy of the mediodorsal thalamus is associated with visual hallucinations in lewy body diseases. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A43.3-A44.	0.9	0
161	Quantification of Total and Mutant Huntingtin Protein Levels in Biospecimens Using a Novel alphaLISA Assay. <i>ENeuro</i> , 2018, 5, ENEURO.0234-18.2018.	0.9	10
162	LRP10 in β -synucleinopathies. <i>Lancet Neurology</i> , The, 2018, 17, 1032-1033.	4.9	11

#	ARTICLE	IF	CITATIONS
163	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. <i>Brain</i> , 2018, 141, 2895-2907.	3.7	39
164	Psychiatric disorders in C9orf72 kindreds. <i>Neurology</i> , 2018, 91, e1498-e1507.	1.5	75
165	Intrafamilial Phenotypic Variability in the C9orf72 Gene Expansion: 2 Case Studies. <i>Frontiers in Psychology</i> , 2018, 9, 1615.	1.1	9
166	Reply: Will FTLD-tau work for all when FTDP-17 retires?. <i>Brain</i> , 2018, 141, e63-e63.	3.7	3
167	Reduced glucocerebrosidase activity in monocytes from patients with Parkinson's disease. <i>Scientific Reports</i> , 2018, 8, 15446.	1.6	82
168	Impact of small vessel disease on severity of motor and cognitive impairment in Parkinson's disease. <i>Journal of Clinical Neuroscience</i> , 2018, 58, 70-74.	0.8	19
169	Nigrostriatal pathology with reduced astrocytes in LRRK2 S910/S935 phosphorylation deficient knockin mice. <i>Neurobiology of Disease</i> , 2018, 120, 76-87.	2.1	16
170	Lipidomics Analysis of Behavioral Variant Frontotemporal Dementia: A Scope for Biomarker Development. <i>Frontiers in Neurology</i> , 2018, 9, 104.	1.1	36
171	Movement disorder society criteria for clinically established early Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1643-1646.	2.2	114
172	Validation of the MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1601-1608.	2.2	171
173	Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain. <i>Translational Psychiatry</i> , 2017, 7, e1003-e1003.	2.4	56
174	Selective neuronal vulnerability in Parkinson disease. <i>Nature Reviews Neuroscience</i> , 2017, 18, 101-113.	4.9	711
175	ALS/FTLD: experimental models and reality. <i>Acta Neuropathologica</i> , 2017, 133, 177-196.	3.9	78
176	Mouse models of frontotemporal dementia: A comparison of phenotypes with clinical symptomatology. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 74, 126-138.	2.9	23
177	Accelerated aging exacerbates a pre-existing pathology in a tau transgenic mouse model. <i>Aging Cell</i> , 2017, 16, 377-386.	3.0	29
178	Predicting Development of Amyotrophic Lateral Sclerosis in Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 163-170.	1.2	17
179	von Economo Neuron Density and Thalamus Volumes in Behavioral Deficits in Frontotemporal Dementia Cases with and without a C9ORF72 Repeat Expansion. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 701-709.	1.2	30
180	The midbrain-to-pons ratio distinguishes progressive supranuclear palsy from non-fluent primary progressive aphasias. <i>European Journal of Neurology</i> , 2017, 24, 956-965.	1.7	11

#	ARTICLE	IF	CITATIONS
181	Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient. <i>Annals of Neurology</i> , 2017, 81, 46-57.	2.8	72
182	Authors' response to a reply to "A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients". <i>British Journal of Dermatology</i> , 2017, 176, 552-553.	1.4	2
183	LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies. <i>Movement Disorders</i> , 2017, 32, 423-432.	2.2	39
184	Amyotrophic lateral sclerosis-like superoxide dismutase 1 proteinopathy is associated with neuronal loss in Parkinson's disease brain. <i>Acta Neuropathologica</i> , 2017, 134, 113-127.	3.9	78
185	Early-life decline in neurogenesis markers and age-related changes of TrkB splice variant expression in the human subependymal zone. <i>European Journal of Neuroscience</i> , 2017, 46, 1768-1778.	1.2	7
186	Diagnosis and management of dementia with Lewy bodies. <i>Neurology</i> , 2017, 89, 88-100.	1.5	2,805
187	Multisite Assessment of Aging-Related Tau Astroglialopathy (ARTAG). <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 605-619.	0.9	38
188	Parkinson disease. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17013.	18.1	3,048
189	The neural correlates and clinical characteristics of psychosis in the frontotemporal dementia continuum and the C9orf72 expansion. <i>NeuroImage: Clinical</i> , 2017, 13, 439-445.	1.4	60
190	Parkinson's Disease Is Not Simply a Prion Disorder. <i>Journal of Neuroscience</i> , 2017, 37, 9799-9807.	1.7	144
191	Subcellular compartmentalisation of copper, iron, manganese, and zinc in the Parkinson's disease brain. <i>Metallomics</i> , 2017, 9, 1447-1455.	1.0	89
192	Pathology and hippocampal atrophy in Alzheimer's disease. <i>Lancet Neurology</i> , The, 2017, 16, 862-864.	4.9	87
193	The hummingbird identifies psp among patients with non-fluent primary progressive aphasia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, e1.19-e1.	0.9	0
194	Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. <i>Movement Disorders</i> , 2017, 32, 1264-1310.	2.2	608
195	Assessment of amyloid β^2 in pathologically confirmed frontotemporal dementia syndromes. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 9, 10-20.	1.2	38
196	Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease. <i>Experimental Neurology</i> , 2017, 298, 202-209.	2.0	73
197	Exploring the Phenotype in Mild Cognitive Impairment to Aid the Prediction of Those at Risk of Transitioning to Parkinson Disease and Dementia With Lewy Bodies. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2017, 30, 196-205.	1.2	8
198	Clinical Aspects of Alzheimer's Disease. <i>Advances in Neurobiology</i> , 2017, 15, 31-53.	1.3	10

#	ARTICLE	IF	CITATIONS
199	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2017, 49, 214.e13-214.e15.	1.5	12
200	Gene therapy for Parkinson's disease: Disease modification by GDNF family of ligands. <i>Neurobiology of Disease</i> , 2017, 97, 179-188.	2.1	40
201	Toll-like receptor 2 is increased in neurons in Parkinson's disease brain and may contribute to alpha-synuclein pathology. <i>Acta Neuropathologica</i> , 2017, 133, 303-319.	3.9	200
202	Increased aneuploidy is not a universal feature across α -synucleinopathies. <i>Movement Disorders</i> , 2017, 32, 475-476.	2.2	5
203	Lipid Metabolism and Survival Across the Frontotemporal Dementia-Amyotrophic Lateral Sclerosis Spectrum: Relationships to Eating Behavior and Cognition. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 773-783.	1.2	47
204	[S3 ⁰¹]: MIXED PATHOLOGY IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P877.	0.4	0
205	White matter changes in frontotemporal dementia and the C9ORF72 gene expansions. <i>Journal of the Neurological Sciences</i> , 2017, 381, 803.	0.3	0
206	Aphasia in Progressive Supranuclear Palsy: As Severe as Progressive Non-Fluent Aphasia. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 705-715.	1.2	20
207	Deletion of Alzheimer's Disease Risk Gene ABCA7 Alters White Adipose Tissue Development and Leptin Levels. <i>Journal of Alzheimer's Disease Reports</i> , 2017, 1, 237-247.	1.2	4
208	α -Synuclein Regulates Neuronal Cholesterol Efflux. <i>Molecules</i> , 2017, 22, 1769.	1.7	29
209	Distinct TDP-43 inclusion morphologies in frontotemporal lobar degeneration with and without amyotrophic lateral sclerosis. <i>Acta Neuropathologica Communications</i> , 2017, 5, 76.	2.4	27
210	Decline in Proliferation and Immature Neuron Markers in the Human Subependymal Zone during Aging: Relationship to EGF- and FGF-Related Transcripts. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 274.	1.7	41
211	ROCK1 Is Associated with Alzheimer's Disease-Specific Plaques, as well as Enhances Autophagosome Formation But not Autophagic $A\beta$ Clearance. <i>Frontiers in Cellular Neuroscience</i> , 2016, 10, 253.	1.8	23
212	Role of the Long Non-Coding RNA MAPT-AS1 in Regulation of Microtubule Associated Protein Tau (MAPT) Expression in Parkinson's Disease. <i>PLoS ONE</i> , 2016, 11, e0157924.	1.1	68
213	Mannose 6-Phosphate Receptor Is Reduced in α -Synuclein Overexpressing Models of Parkinson's Disease. <i>PLoS ONE</i> , 2016, 11, e0160501.	1.1	19
214	Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers. <i>Movement Disorders</i> , 2016, 31, 889-897.	2.2	76
215	A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients. <i>British Journal of Dermatology</i> , 2016, 175, 1073-1075.	1.4	88
216	Neuropathology of α -synuclein propagation and Braak hypothesis. <i>Movement Disorders</i> , 2016, 31, 152-160.	2.2	111

#	ARTICLE	IF	CITATIONS
217	Cerebellar neuronal loss in amyotrophic lateral sclerosis cases with <scp>ATXN</scp>2 intermediate repeat expansions. <i>Annals of Neurology</i> , 2016, 79, 295-305.	2.8	29
218	Oral nicotinamide reduces transepidermal water loss: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2016, 175, 1363-1365.	1.4	16
219	Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker. <i>Scientific Reports</i> , 2016, 6, 31391.	1.6	32
220	Neuronal network disintegration: common pathways linking neurodegenerative diseases. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1234-1241.	0.9	106
221	ABCA7 Mediates Phagocytic Clearance of Amyloid- β^2 in the Brain. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 569-584.	1.2	69
222	MicroRNA-146a suppresses ROCK1 allowing hyperphosphorylation of tau in Alzheimer's disease. <i>Scientific Reports</i> , 2016, 6, 26697.	1.6	84
223	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 862-871.	0.4	93
224	TDP-43 in the hypoglossal nucleus identifies amyotrophic lateral sclerosis in behavioral variant frontotemporal dementia. <i>Journal of the Neurological Sciences</i> , 2016, 366, 197-201.	0.3	10
225	The new definition and diagnostic criteria of Parkinson's disease. <i>Lancet Neurology</i> , The, 2016, 15, 546-548.	4.9	82
226	A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein. <i>Molecular Neurodegeneration</i> , 2016, 11, 61.	4.4	39
227	Abolishing the 1-year rule: How much evidence will be enough?. <i>Movement Disorders</i> , 2016, 31, 1623-1627.	2.2	43
228	Characterization of circular <scp>RNA</scp>s landscape in multiple system atrophy brain. <i>Journal of Neurochemistry</i> , 2016, 139, 485-496.	2.1	79
229	Motor cortical function determines prognosis in sporadic ALS. <i>Neurology</i> , 2016, 87, 513-520.	1.5	76
230	Expanding the phenotypic associations of globular glial tau subtypes. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 4, 6-13.	1.2	23
231	Cognition and eating behavior in amyotrophic lateral sclerosis: effect on survival. <i>Journal of Neurology</i> , 2016, 263, 1593-1603.	1.8	48
232	Animal modeling an oligodendroglialopathy " multiple system atrophy. <i>Acta Neuropathologica Communications</i> , 2016, 4, 12.	2.4	16
233	Amyotrophic lateral sclerosis and frontotemporal dementia: distinct and overlapping changes in eating behaviour and metabolism. <i>Lancet Neurology</i> , The, 2016, 15, 332-342.	4.9	120
234	Cerebellar atrophy in Parkinson's disease and its implication for network connectivity. <i>Brain</i> , 2016, 139, 845-855.	3.7	103

#	ARTICLE	IF	CITATIONS
235	Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. <i>Neurobiology of Aging</i> , 2016, 38, 214.e7-214.e10.	1.5	78
236	Ageing-related tau astroglialopathy (ARTAG): harmonized evaluation strategy. <i>Acta Neuropathologica</i> , 2016, 131, 87-102.	3.9	380
237	The substantia nigra and ventral tegmental dopaminergic neurons from development to degeneration. <i>Journal of Chemical Neuroanatomy</i> , 2016, 76, 98-107.	1.0	54
238	Variants in the SNCA gene associate with motor progression while variants in the MAPT gene associate with the severity of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 24, 89-94.	1.1	28
239	Distinctive pathological mechanisms involved in primary progressive Aphasias. <i>Neurobiology of Aging</i> , 2016, 38, 82-92.	1.5	45
240	Impulsivity, decreased social exploration, and executive dysfunction in a mouse model of frontotemporal dementia. <i>Neurobiology of Learning and Memory</i> , 2016, 130, 34-43.	1.0	24
241	The frontotemporal dementia-motor neuron disease continuum. <i>Lancet, The</i> , 2016, 388, 919-931.	6.3	294
242	Strand-specific RNA-sequencing analysis of multiple system atrophy brain transcriptome. <i>Neuroscience</i> , 2016, 322, 234-250.	1.1	24
243	MDS research criteria for prodromal Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1600-1611.	2.2	1,033
244	Neuropathologic assessment of participants in two multicenter longitudinal observational studies: The Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN). <i>Neuropathology</i> , 2015, 35, 390-400.	0.7	68
245	The relationships between mild cognitive impairment and phenotype in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2015, 1, 15015.	2.5	20
246	Abnormal connectivity between the default mode and the visual system underlies the manifestation of visual hallucinations in Parkinson's disease: a task-based fMRI study. <i>Npj Parkinson's Disease</i> , 2015, 1, 15003.	2.5	75
247	Fatty Acid Composition of the Anterior Cingulate Cortex Indicates a High Susceptibility to Lipid Peroxidation in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 175-185.	1.5	16
248	Early in vivo Effects of the Human Mutant Amyloid- β 2 Protein Precursor (hA β 2PPSwInd) on the Mouse Olfactory Bulb. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 443-457.	1.2	5
249	Validation of the Psychosis and Hallucinations Questionnaire in Non-demented Patients with Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 175-181.	0.8	28
250	Restricted disease propagation in multiple system atrophy with prolonged survival. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 681-685.	1.8	4
251	Selective loss of oxytocin and vasopressin in the hypothalamus in early Huntington disease: a case study. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 843-848.	1.8	31
252	Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1639-1647.	2.2	123

#	ARTICLE	IF	CITATIONS
253	Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias. <i>Movement Disorders</i> , 2015, 30, 796-804.	2.2	32
254	Terra incognita—cerebellar contributions to neuropsychiatric and cognitive dysfunction in behavioral variant frontotemporal dementia. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 121.	1.7	23
255	SNCA Gene, but Not MAPT, Influences Onset Age of Parkinson's Disease in Chinese and Australians. <i>BioMed Research International</i> , 2015, 2015, 1-6.	0.9	16
256	Aneuploidy in Lewy body diseases. <i>Neurobiology of Aging</i> , 2015, 36, 1253-1260.	1.5	23
257	Progressive supranuclear palsy finally has a clinically measurable α abnormality. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 241-241.	0.9	0
258	MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1591-1601.	2.2	4,389
259	F2-03-04: Genetic risk factors for posterior cortical atrophy. , 2015, 11, P168-P169.		2
260	Unusual α -synuclein and cerebellar pathologies in a case of hereditary myoclonus-dystonia without <i>SCGE</i> mutation. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 837-842.	1.8	1
261	PART is part of Alzheimer disease. <i>Acta Neuropathologica</i> , 2015, 129, 749-756.	3.9	256
262	TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes. <i>Brain</i> , 2015, 138, 3110-3122.	3.7	94
263	Re-evaluating the glio-centric view of multiple system atrophy by highlighting the neuronal involvement: Figure 1. <i>Brain</i> , 2015, 138, 2116-2119.	3.7	21
264	Transcriptome analysis of grey and white matter cortical tissue in multiple system atrophy. <i>Neurogenetics</i> , 2015, 16, 107-122.	0.7	33
265	Long intervening non-coding RNA 00320 is human brain-specific and highly expressed in the cortical white matter. <i>Neurogenetics</i> , 2015, 16, 201-213.	0.7	18
266	High expression of long intervening non-coding RNA OLMALINC in the human cortical white matter is associated with regulation of oligodendrocyte maturation. <i>Molecular Brain</i> , 2015, 8, 2.	1.3	25
267	Early-onset axonal pathology in a novel <i>P301S</i> transgenic mouse model of frontotemporal lobar degeneration. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 906-925.	1.8	41
268	FTD and ALS—translating mouse studies into clinical trials. <i>Nature Reviews Neurology</i> , 2015, 11, 360-366.	4.9	64
269	Generation and characterization of novel conformation-specific monoclonal antibodies for α -synuclein pathology. <i>Neurobiology of Disease</i> , 2015, 79, 81-99.	2.1	116
270	Protective properties of lysozyme on β -amyloid pathology: implications for Alzheimer disease. <i>Neurobiology of Disease</i> , 2015, 83, 122-133.	2.1	58

#	ARTICLE	IF	CITATIONS
271	Progression in Behavioral Variant Frontotemporal Dementia. <i>JAMA Neurology</i> , 2015, 72, 1501.	4.5	47
272	Spread of pathology in amyotrophic lateral sclerosis: assessment of phosphorylated TDP-43 along axonal pathways. <i>Acta Neuropathologica Communications</i> , 2015, 3, 47.	2.4	69
273	The differentiation of progressive supranuclear palsy. <i>Neurodegenerative Disease Management</i> , 2015, 5, 385-388.	1.2	2
274	Long noncoding RNAs in TDP-43 and FUS/TLS-related frontotemporal lobar degeneration (FTLD). <i>Neurobiology of Disease</i> , 2015, 82, 445-454.	2.1	33
275	Short-term suppression of A315T mutant human TDP-43 expression improves functional deficits in a novel inducible transgenic mouse model of FTLD-TDP and ALS. <i>Acta Neuropathologica</i> , 2015, 130, 661-678.	3.9	61
276	Evidence for α -synuclein prions causing multiple system atrophy in humans with parkinsonism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E5308-17.	3.3	578
277	IsCHCHD10Pro34Ser pathogenic for frontotemporal dementia and amyotrophic lateral sclerosis?: Figure 1. <i>Brain</i> , 2015, 138, e385-e385.	3.7	16
278	Eating behavior in frontotemporal dementia. <i>Neurology</i> , 2015, 85, 1310-1317.	1.5	72
279	β -dependent reduction of NCAM2-mediated synaptic adhesion contributes to synapse loss in Alzheimer's disease. <i>Nature Communications</i> , 2015, 6, 8836.	5.8	70
280	The role of transcriptional control in multiple system atrophy. <i>Neurobiology of Aging</i> , 2015, 36, 394-400.	1.5	10
281	Reply: Lysosomal dysfunction in Parkinson's disease. <i>Brain</i> , 2015, 138, e340-e340.	3.7	1
282	Inflammation is genetically implicated in Parkinson's disease. <i>Neuroscience</i> , 2015, 302, 89-102.	1.1	182
283	Effect of PSEN1 mutations on MAPT methylation in early-onset Alzheimer's disease. <i>Current Alzheimer Research</i> , 2015, 12, 745-751.	0.7	9
284	Influence of Single Nucleotide Polymorphisms in <i>COMT</i> , <i>MAO-A</i> , and <i>BDNF</i> Genes on Dyskinesias and Levodopa Use in Parkinson's Disease. <i>Neurodegenerative Diseases</i> , 2014, 13, 24-28.	0.8	56
285	Increased <i>Ndfip1</i> in the Substantia Nigra of Parkinsonian Brains Is Associated with Elevated Iron Levels. <i>PLoS ONE</i> , 2014, 9, e87119.	1.1	28
286	Cerebellar Integrity in the Amyotrophic Lateral Sclerosis - Frontotemporal Dementia Continuum. <i>PLoS ONE</i> , 2014, 9, e105632.	1.1	79
287	Parkinson's disease-implicated kinases in the brain; insights into disease pathogenesis. <i>Frontiers in Molecular Neuroscience</i> , 2014, 7, 57.	1.4	73
288	Analysis of Tyrosine Hydroxylase Isoforms and Phosphorylation in Parkinson's Disease. , 2014, , 15.		0

#	ARTICLE	IF	CITATIONS
289	Exploring Myelin Dysfunction in Multiple System Atrophy. <i>Experimental Neurobiology</i> , 2014, 23, 337-344.	0.7	33
290	ABCA5 Regulates Amyloid- β Peptide Production and is Associated with Alzheimer's Disease Neuropathology. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 857-869.	1.2	40
291	Altered lipid levels provide evidence for myelin dysfunction in multiple system atrophy. <i>Acta Neuropathologica Communications</i> , 2014, 2, 150.	2.4	62
292	Alpha-synuclein biology in Lewy body diseases. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 73.	3.0	288
293	Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. <i>Human Molecular Genetics</i> , 2014, 23, 6139-6146.	1.4	178
294	H04 Gene Expression Changes In Emotion And Metabolism Regulating Neuropeptide Systems In The Hypothalamus In Clinical Huntington Disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, A53-A53.	0.9	0
295	DNA methylation of the <i>MAPT</i> gene in Parkinson's disease cohorts and modulation by vitamin E <i>In Vitro</i> . <i>Movement Disorders</i> , 2014, 29, 1606-1614.	2.2	79
296	Visual hallucinations in Parkinson's disease: Theoretical models. <i>Movement Disorders</i> , 2014, 29, 1591-1598.	2.2	70
297	The role of dysfunctional attentional control networks in visual misperceptions in Parkinson's disease. <i>Human Brain Mapping</i> , 2014, 35, 2206-2219.	1.9	111
298	Systemic metabolism in frontotemporal dementia. <i>Neurology</i> , 2014, 83, 1812-1818.	1.5	48
299	Prodegenerative β expression in oligodendroglial α -synuclein models of multiple system atrophy. <i>Neurobiology of Disease</i> , 2014, 63, 171-183.	2.1	10
300	c-Abl phosphorylates α -synuclein and regulates its degradation: implication for α -synuclein clearance and contribution to the pathogenesis of Parkinson's disease. <i>Human Molecular Genetics</i> , 2014, 23, 2858-2879.	1.4	176
301	Lipid dysfunction and pathogenesis of multiple system atrophy. <i>Acta Neuropathologica Communications</i> , 2014, 2, 15.	2.4	40
302	TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. <i>Acta Neuropathologica</i> , 2014, 127, 407-418.	3.9	123
303	The neurobiological basis of cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 634-650.	2.2	282
304	Beyond the temporal pole: limbic memory circuit in the semantic variant of primary progressive aphasia. <i>Brain</i> , 2014, 137, 2065-2076.	3.7	50
305	α -Synucleinopathy phenotypes. <i>Parkinsonism and Related Disorders</i> , 2014, 20, S62-S67.	1.1	272
306	Reduced glucocerebrosidase is associated with increased α -synuclein in sporadic Parkinson's disease. <i>Brain</i> , 2014, 137, 834-848.	3.7	397

#	ARTICLE	IF	CITATIONS
307	Copper pathology in vulnerable brain regions in Parkinson's disease. <i>Neurobiology of Aging</i> , 2014, 35, 858-866.	1.5	188
308	Longitudinal white matter changes in frontotemporal dementia subtypes. <i>Human Brain Mapping</i> , 2014, 35, 3547-3557.	1.9	77
309	Glucocerebrosidase deficits in sporadic Parkinson disease. <i>Autophagy</i> , 2014, 10, 1350-1351.	4.3	49
310	New criteria for frontotemporal dementia syndromes: clinical and pathological diagnostic implications. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 865-870.	0.9	195
311	Misfolded proteins in Huntington disease fetal grafts: Further evidence of cell-to-cell transfer?. <i>Annals of Neurology</i> , 2014, 76, 20-21.	2.8	2
312	Heritability in frontotemporal dementia: more missing pieces?. <i>Journal of Neurology</i> , 2014, 261, 2170-2177.	1.8	27
313	Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease. <i>Brain</i> , 2014, 137, 2493-2508.	3.7	232
314	Biomarkers in dementia: clinical utility and new directions. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 1426-1434.	0.9	119
315	Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 518-526.	2.2	112
316	Frontotemporal dementia and its subtypes: a genome-wide association study. <i>Lancet Neurology</i> , The, 2014, 13, 686-699.	4.9	302
317	Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 454-462.	2.2	379
318	Tricks of the mind: Visual hallucinations as disorders of attention. <i>Progress in Neurobiology</i> , 2014, 116, 58-65.	2.8	156
319	Distribution of Pathology in Frontal Variant Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 63-70.	1.2	53
320	P1-039: MAPT METHYLATION IN ALZHEIMER'S DISEASE. , 2014, 10, P317-P318.		3
321	DAT-SPECT diagnoses dopamine depletion, but not PD. <i>Movement Disorders</i> , 2014, 29, 1705-1706.	2.2	16
322	Alpha Synuclein in Parkinson's Disease. , 2014, , 691-726.		4
323	The Role of Astrocytes in Parkinson's Disease. , 2014, , 127-144.		3
324	Systems-Based Analyses of Brain Regions Functionally Impacted in Parkinson's Disease Reveals Underlying Causal Mechanisms. <i>PLoS ONE</i> , 2014, 9, e102909.	1.1	74

#	ARTICLE	IF	CITATIONS
325	Variability in neuronal expression of dopamine receptors and transporters in the substantia nigra. <i>Movement Disorders</i> , 2013, 28, 1351-1359.	2.2	20
326	Classification of FTL-D-TDP cases into pathological subtypes using antibodies against phosphorylated and non-phosphorylated TDP43. <i>Acta Neuropathologica Communications</i> , 2013, 1, 33.	2.4	48
327	The pathogenesis of cingulate atrophy in behavioral variant frontotemporal dementia and Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2013, 1, 30.	2.4	17
328	ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies. <i>Acta Neuropathologica Communications</i> , 2013, 1, 11.	2.4	61
329	Pathway Analysis of the Human Brain Transcriptome in Disease. <i>Journal of Molecular Neuroscience</i> , 2013, 51, 28-36.	1.1	17
330	Can we clinically diagnose dementia with Lewy bodies yet?. <i>Translational Neurodegeneration</i> , 2013, 2, 4.	3.6	43
331	Frontotemporal dementia's amyotrophic lateral sclerosis syndrome locus on chromosome 16p12.1-q12.2: genetic, clinical and neuropathological analysis. <i>Acta Neuropathologica</i> , 2013, 125, 523-533.	3.9	24
332	Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. <i>Brain</i> , 2013, 136, 2419-2431.	3.7	965
333	Cortical limb myoclonus in pathologically proven progressive supranuclear palsy. <i>Movement Disorders</i> , 2013, 28, 1804-1806.	2.2	2
334	Trophic factors differentiate dopamine neurons vulnerable to Parkinson's disease. <i>Neurobiology of Aging</i> , 2013, 34, 873-886.	1.5	44
335	Motor deficits associated with changes in β -amyloid in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 475-476.	0.9	1
336	An Improved High-Throughput Lipid Extraction Method for the Analysis of Human Brain Lipids. <i>Lipids</i> , 2013, 48, 307-318.	0.7	76
337	DNA extraction from fresh-frozen and formalin-fixed, paraffin-embedded human brain tissue. <i>Neuroscience Bulletin</i> , 2013, 29, 649-654.	1.5	25
338	Mutations in protein N-arginine methyltransferases are not the cause of FTL-D-FUS. <i>Neurobiology of Aging</i> , 2013, 34, 2235.e11-2235.e13.	1.5	13
339	LRRK2 interactions with β -synuclein in Parkinson's disease brains and in cell models. <i>Journal of Molecular Medicine</i> , 2013, 91, 513-522.	1.7	68
340	Unlocking the secrets of LRRK2 function with selective kinase inhibitors. <i>Future Neurology</i> , 2013, 8, 347-357.	0.9	4
341	Localization of copper and copper transporters in the human brain. <i>Metallomics</i> , 2013, 5, 43-51.	1.0	121
342	ABCA8 stimulates sphingomyelin production in oligodendrocytes. <i>Biochemical Journal</i> , 2013, 452, 401-410.	1.7	40

#	ARTICLE	IF	CITATIONS
343	Endogenous progesterone levels and frontotemporal dementia: modulation of TDP-43 and Tau levels in vitro and treatment of the A315T TARDBP mouse model. <i>DMM Disease Models and Mechanisms</i> , 2013, 6, 1198-204.	1.2	10
344	Retrosplenial Cortex (BA 29) Volumes in Behavioral Variant Frontotemporal Dementia and Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2013, 35, 177-182.	0.7	24
345	Tenuigenin Attenuates α -Synuclein-Induced Cytotoxicity by Down-Regulating Polo-Like Kinase 3. <i>CNS Neuroscience and Therapeutics</i> , 2013, 19, 688-694.	1.9	15
346	Increased Expression of ABCA8 in Multiple System Atrophy Brain is Associated with Changes in Pathogenic Proteins. <i>Journal of Parkinson's Disease</i> , 2013, 3, 331-339.	1.5	19
347	A Multicenter Study of Glucocerebrosidase Mutations in Dementia With Lewy Bodies. <i>JAMA Neurology</i> , 2013, 70, 727.	4.5	374
348	Measurement of LRRK2 and Ser910/935 Phosphorylated LRRK2 in Peripheral Blood Mononuclear Cells from Idiopathic Parkinson's Disease Patients. <i>Journal of Parkinson's Disease</i> , 2013, 3, 145-152.	1.5	44
349	FAS-Dependent Cell Death in α -Synuclein Transgenic Oligodendrocyte Models of Multiple System Atrophy. <i>PLoS ONE</i> , 2013, 8, e55243.	1.1	28
350	Elevation in Sphingomyelin Synthase Activity Is Associated with Increases in Amyloid-Beta Peptide Generation. <i>PLoS ONE</i> , 2013, 8, e74016.	1.1	17
351	Unique Transcriptome Patterns of the White and Grey Matter Corroborate Structural and Functional Heterogeneity in the Human Frontal Lobe. <i>PLoS ONE</i> , 2013, 8, e78480.	1.1	40
352	<i>C9ORF72</i> repeat expansion in clinical and neuropathologic frontotemporal dementia cohorts. <i>Neurology</i> , 2012, 79, 995-1001.	1.5	108
353	In vivo and post-mortem memory circuit integrity in frontotemporal dementia and Alzheimer's disease. <i>Brain</i> , 2012, 135, 3015-3025.	3.7	157
354	Is Seladin-1 Really a Selective Alzheimer's Disease Indicator?. <i>Journal of Alzheimer's Disease</i> , 2012, 30, 35-39.	1.2	22
355	Nicotinamide reduces photodynamic therapy-induced immunosuppression in humans. <i>British Journal of Dermatology</i> , 2012, 167, 631-636.	1.4	25
356	Srp20 regulates TrkB pre-mRNA splicing to generate TrkB ^{Shc} transcripts with implications for Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2012, 123, 159-171.	2.1	28
357	An evidence base for noradrenergic deficits in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 1589-1591.	2.2	7
358	Mechanisms of disease in frontotemporal lobar degeneration: gain of function versus loss of function effects. <i>Acta Neuropathologica</i> , 2012, 124, 373-382.	3.9	89
359	Changes in Sphingomyelin Level Affect Alpha-Synuclein and ABCA5 Expression. <i>Journal of Parkinson's Disease</i> , 2012, 2, 41-46.	1.5	29
360	Amyloid beta selectively modulates neuronal TrkB alternative transcript expression with implications for Alzheimer's disease. <i>Neuroscience</i> , 2012, 210, 363-374.	1.1	33

#	ARTICLE	IF	CITATIONS
361	Role of hippocalcin in mediating A β toxicity. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012, 1822, 1247-1257.	1.8	12
362	Small-vessel disease in patients with Parkinson's disease: A clinicopathological study. <i>Movement Disorders</i> , 2012, 27, 1506-1512.	2.2	49
363	Multiple Biological Pathways Link Cognitive Lifestyle to Protection from Dementia. <i>Biological Psychiatry</i> , 2012, 71, 783-791.	0.7	83
364	Reduced T helper and B lymphocytes in Parkinson's disease. <i>Journal of Neuroimmunology</i> , 2012, 252, 95-99.	1.1	158
365	An emerging role for LRRK2 in the immune system. <i>Biochemical Society Transactions</i> , 2012, 40, 1134-1139.	1.6	36
366	Substantia Nigra, Ventral Tegmental Area, and Retrorubral Fields. , 2012, , 439-455.		23
367	Aspects of Innate Immunity and Parkinson's Disease. <i>Frontiers in Pharmacology</i> , 2012, 3, 33.	1.6	17
368	A cytoarchitectonic and chemoarchitectonic analysis of the dopamine cell groups in the substantia nigra, ventral tegmental area, and retrorubral field in the mouse. <i>Brain Structure and Function</i> , 2012, 217, 591-612.	1.2	136
369	Leucine-rich repeat kinase 2 and alternative splicing in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 1004-1011.	2.2	13
370	Anterior cingulate integrity: Executive and neuropsychiatric features in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 1262-1267.	2.2	45
371	Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson's disease?. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 673-686.	1.4	63
372	GIRK2 expression in dopamine neurons of the substantia nigra and ventral tegmental area. <i>Journal of Comparative Neurology</i> , 2012, 520, 2591-2607.	0.9	76
373	Macroautophagy in sporadic and the genetic form of Parkinson's disease with the A53T α -synuclein mutation. <i>Translational Neurodegeneration</i> , 2012, 1, 2.	3.6	24
374	Investigating visual misperceptions in Parkinson's disease: A novel behavioral paradigm. <i>Movement Disorders</i> , 2012, 27, 500-505.	2.2	41
375	The relationship between clinical and pathological variables in Richardson's syndrome. <i>Journal of Neurology</i> , 2012, 259, 482-490.	1.8	19
376	Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 1033-1037.	0.9	151
377	Isoform-specific proteolysis of apolipoprotein-E in the brain. <i>Neurobiology of Aging</i> , 2011, 32, 257-271.	1.5	49
378	Interaction between α -Synuclein and Tau Genotypes and the Progression of Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2011, 1, 271-276.	1.5	14

#	ARTICLE	IF	CITATIONS
379	Genetic Polymorphisms in Sigma-1 Receptor and Apolipoprotein E Interact to Influence the Severity of Alzheimers Disease. <i>Current Alzheimer Research</i> , 2011, 8, 765-770.	0.7	48
380	Overview and recent advances in neuropathology. Part 2: Neurodegeneration. <i>Pathology</i> , 2011, 43, 93-102.	0.3	7
381	An action spectrum for ultraviolet radiation-induced immunosuppression in humans. <i>British Journal of Dermatology</i> , 2011, 164, no-no.	1.4	90
382	Changes in the solubility and phosphorylation of α -synuclein over the course of Parkinson's disease. <i>Acta Neuropathologica</i> , 2011, 121, 695-704.	3.9	108
383	Neuropathology underlying clinical variability in patients with synucleinopathies. <i>Acta Neuropathologica</i> , 2011, 122, 187-204.	3.9	357
384	Striatal β -amyloid in dementia with Lewy bodies but not Parkinson's disease. <i>Journal of Neural Transmission</i> , 2011, 118, 713-719.	1.4	82
385	Pathological Staging of Frontotemporal Lobar Degeneration. <i>Journal of Molecular Neuroscience</i> , 2011, 45, 379-383.	1.1	26
386	Cortical atrophy differentiates Richardson's syndrome from the parkinsonian form of progressive supranuclear palsy. <i>Movement Disorders</i> , 2011, 26, 256-263.	2.2	43
387	Clinical correlates of similar pathologies in parkinsonian syndromes. <i>Movement Disorders</i> , 2011, 26, 499-506.	2.2	17
388	Glia: Initiators and progressors of pathology in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 6-17.	2.2	383
389	Milestones in Parkinson's disease—Clinical and pathologic features. <i>Movement Disorders</i> , 2011, 26, 1015-1021.	2.2	150
390	Visual misperceptions and hallucinations in Parkinson's disease: Dysfunction of attentional control networks?. <i>Movement Disorders</i> , 2011, 26, 2154-2159.	2.2	164
391	Eating and hypothalamus changes in behavioral variant frontotemporal dementia. <i>Annals of Neurology</i> , 2011, 69, 312-319.	2.8	158
392	Genetic and Clinical Features of Progranulin-Associated Frontotemporal Lobar Degeneration. <i>Archives of Neurology</i> , 2011, 68, 488.	4.9	108
393	Clinical phenotypes in autopsy-confirmed Pick disease. <i>Neurology</i> , 2011, 76, 253-259.	1.5	42
394	Utility and Limitations of Addenbrooke's Cognitive Examination-Revised for Detecting Mild Cognitive Impairment in Parkinson's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 31, 349-357.	0.7	27
395	Lipid Pathway Alterations in Parkinson's Disease Primary Visual Cortex. <i>PLoS ONE</i> , 2011, 6, e17299.	1.1	142
396	A23...Changes in key hypothalamic neuropeptide populations in Huntington's Disease revealed by neuropathological analyses. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, A7.3-A8.	0.9	0

#	ARTICLE	IF	CITATIONS
397	Low Serum Progranulin Predicts the Presence of Mutations: A Prospective Study. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 981-984.	1.2	54
398	Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. <i>Acta Neuropathologica</i> , 2010, 119, 1-4.	3.9	854
399	Focal demyelination in Alzheimer's disease and transgenic mouse models. <i>Acta Neuropathologica</i> , 2010, 119, 567-577.	3.9	155
400	FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , 2010, 120, 33-41.	3.9	222
401	Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses. <i>Acta Neuropathologica</i> , 2010, 120, 777-788.	3.9	93
402	Apolipoprotein-E forms dimers in human frontal cortex and hippocampus. <i>BMC Neuroscience</i> , 2010, 11, 23.	0.8	25
403	Pigmentation in the human brain and risk of Parkinson's disease. <i>Annals of Neurology</i> , 2010, 67, 553-554.	2.8	4
404	Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration—motor neuron disease. <i>Annals of Neurology</i> , 2010, 68, 639-649.	2.8	168
405	Effect of age on proliferation-regulating factors in human adult neurogenic regions. <i>Journal of Neurochemistry</i> , 2010, 115, 956-964.	2.1	24
406	Immunohistochemical evidence for macroautophagy in neurones and endothelial cells in Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2010, 36, 312-319.	1.8	70
407	Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. <i>Nature Genetics</i> , 2010, 42, 234-239.	9.4	479
408	Missing pieces in the Parkinson's disease puzzle. <i>Nature Medicine</i> , 2010, 16, 653-661.	15.2	621
409	Reply to: "Being too inclusive about synuclein inclusions". <i>Nature Medicine</i> , 2010, 16, 961-961.	15.2	0
410	The progression of pathology in Parkinson's disease. <i>Annals of the New York Academy of Sciences</i> , 2010, 1184, 188-195.	1.8	214
411	Increased ATP-Binding Cassette Transporter A1 Expression in Alzheimer's Disease Hippocampal Neurons. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 193-205.	1.2	39
412	Pathology of Parkinson's Disease. <i>Blue Books of Neurology</i> , 2010, 34, 132-154.	0.1	6
413	The case of a 48 year-old woman with bizarre and complex delusions. <i>Nature Reviews Neurology</i> , 2010, 6, 175-179.	4.9	24
414	Very early-onset frontotemporal dementia with no family history predicts underlying fused in sarcoma pathology. <i>Brain</i> , 2010, 133, e158-e158.	3.7	13

#	ARTICLE	IF	CITATIONS
415	Increased expression of the lysosomal cholesterol transporter NPC1 in Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2010, 1801, 831-838.	1.2	32
416	Selective cell death in neurodegeneration: Why are some neurons spared in vulnerable regions?. <i>Progress in Neurobiology</i> , 2010, 92, 316-329.	2.8	106
417	Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. <i>Lancet Neurology</i> , The, 2009, 8, 1150-1157.	4.9	734
418	Do polymorphisms in the familial Parkinsonism genes contribute to risk for sporadic Parkinson's disease?. <i>Movement Disorders</i> , 2009, 24, 833-838.	2.2	56
419	Mitochondrial DNA haplogroups J and K are not protective for Parkinson's disease in the Australian community. <i>Movement Disorders</i> , 2009, 24, 290-292.	2.2	23
420	No Lewy pathology in monkeys with over 10 years of severe MPTP Parkinsonism. <i>Movement Disorders</i> , 2009, 24, 1519-1523.	2.2	72
421	Unilateral rest tremor in vascular parkinsonism associated with a contralateral lesion of the locus coeruleus. <i>Movement Disorders</i> , 2009, 24, 1242-1244.	2.2	6
422	Relative preservation of thalamic centromedian nucleus in parkinsonian patients with dystonia. <i>Movement Disorders</i> , 2009, 24, 2128-2135.	2.2	13
423	Phosphorylation of soluble tau differs in Pick's disease and Alzheimer's disease brains. <i>Journal of Neural Transmission</i> , 2009, 116, 1243-1251.	1.4	35
424	Cytoskeletal alterations differentiate presenilin-1 and sporadic Alzheimer's disease. <i>Acta Neuropathologica</i> , 2009, 117, 19-29.	3.9	26
425	Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. <i>Acta Neuropathologica</i> , 2009, 117, 15-18.	3.9	377
426	Variations in the neuropathology of familial Alzheimer's disease. <i>Acta Neuropathologica</i> , 2009, 118, 37-52.	3.9	112
427	pH measurement as quality control on human <i>post mortem</i> brain tissue: a study of the BrainNet Europe consortium. <i>Neuropathology and Applied Neurobiology</i> , 2009, 35, 329-337.	1.8	93
428	Topical nicotinamide modulates cellular energy metabolism and provides broad-spectrum protection against ultraviolet radiation-induced immunosuppression in humans. <i>British Journal of Dermatology</i> , 2009, 161, 1357-1364.	1.4	75
429	Monocyte Chemoattractant Protein-1 Plays a Dominant Role in the Chronic Inflammation Observed in Alzheimer's Disease. <i>Brain Pathology</i> , 2009, 19, 392-398.	2.1	209
430	Tryptophan is a marker of human postmortem brain tissue quality. <i>Journal of Neurochemistry</i> , 2009, 110, 1400-1408.	2.1	13
431	Intralaminar nuclei of the thalamus in Lewy body diseases. <i>Brain Research Bulletin</i> , 2009, 78, 97-104.	1.4	50
432	Anti-melanin antibodies are increased in sera in Parkinson's disease. <i>Experimental Neurology</i> , 2009, 217, 297-301.	2.0	72

#	ARTICLE	IF	CITATIONS
433	White matter loss in healthy ageing: A postmortem analysis. <i>Neurobiology of Aging</i> , 2009, 30, 1288-1295.	1.5	62
434	The neural basis of semantic memory: Evidence from semantic dementia. <i>Neurobiology of Aging</i> , 2009, 30, 2043-2052.	1.5	47
435	O.064 Thalamic changes in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S17.	1.1	0
436	P3.061 Differential distribution of tyrosine hydroxylase isoforms in the human brain. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S164.	1.1	0
437	Thalamic changes in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S152-S155.	1.1	132
438	Frontotemporal dementia and dementia with Lewy bodies in a case-control study of Alzheimer's disease. <i>International Psychogeriatrics</i> , 2009, 21, 688-695.	0.6	16
439	Degeneration in Different Parkinsonian Syndromes Relates to Astrocyte Type and Astrocyte Protein Expression. <i>Journal of Neuro pathology and Experimental Neurology</i> , 2009, 68, 1073-1083.	0.9	173
440	Variable phenotype of Alzheimer's disease with spastic paraparesis. <i>Journal of Neurochemistry</i> , 2008, 104, 573-583.	2.1	54
441	The comparative biology of neuromelanin and lipofuscin in the human brain. <i>Cellular and Molecular Life Sciences</i> , 2008, 65, 1669-1682.	2.4	166
442	The progression of pathology in longitudinally followed patients with Parkinson's disease. <i>Acta Neuropathologica</i> , 2008, 115, 409-415.	3.9	337
443	Clarifying the pathological progression of Parkinson's disease. <i>Acta Neuropathologica</i> , 2008, 115, 377-378.	3.9	10
444	LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions. <i>Acta Neuropathologica</i> , 2008, 116, 639-646.	3.9	43
445	Excessive dopamine neuron loss in progressive supranuclear palsy. <i>Movement Disorders</i> , 2008, 23, 607-610.	2.2	27
446	The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years. <i>Movement Disorders</i> , 2008, 23, 837-844.	2.2	1,779
447	Haplotype analysis of the IGF2-INS-TH gene cluster in Parkinson's disease. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008, 147B, 495-499.	1.1	17
448	Pedigree with frontotemporal lobar degeneration - motor neuron disease and Tau DNA binding protein-43 positive neuropathology: genetic linkage to chromosome 9. <i>BMC Neurology</i> , 2008, 8, 32.	0.8	71
449	Human-based studies on α -synuclein deposition and relationship to Parkinson's disease symptoms. <i>Experimental Neurology</i> , 2008, 209, 12-21.	2.0	39
450	Neuropathologic correlates of white matter hyperintensities. <i>Neurology</i> , 2008, 71, 804-811.	1.5	291

#	ARTICLE	IF	CITATIONS
451	Clinical Significance of Lobar Atrophy in Frontotemporal Dementia: Application of an MRI Visual Rating Scale. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 23, 334-342.	0.7	150
452	Genetics of Parkinson's Disease. , 2007, , 663-697.		5
453	The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 251-257.	0.9	104
454	The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part II. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 329-336.	0.9	41
455	VISA—A pass to innate immunity. <i>International Journal of Biochemistry and Cell Biology</i> , 2007, 39, 287-291.	1.2	18
456	Tau isoform expression in frontotemporal dementia without tau deposition. <i>Journal of Clinical Neuroscience</i> , 2007, 14, 1182-1185.	0.8	7
457	A functional polymorphism in the parkin gene promoter affects the age of onset of Parkinson's disease. <i>Neuroscience Letters</i> , 2007, 414, 170-173.	1.0	9
458	Substantia nigra echomorphology in the healthy very old: Correlation with motor slowing. <i>NeuroImage</i> , 2007, 34, 1054-1059.	2.1	66
459	p25± Relocalizes in Oligodendroglia from Myelin to Cytoplasmic Inclusions in Multiple System Atrophy. <i>American Journal of Pathology</i> , 2007, 171, 1291-1303.	1.9	169
460	Clinicopathological aspects of motor parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S208-S210.	1.1	7
461	ORGANIZATION: PYRAMIDAL AND EXTRAPYRAMIDAL SYSTEM. , 2007, , 396-401.		0
462	Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's Disease. <i>Movement Disorders</i> , 2007, 22, 982-989.	2.2	34
463	Relationship between neuronal loss and ?inflammatory plaques? in early onset Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2007, 33, 328-333.	1.8	11
464	Parkin Co-regulated Gene (PACRG) is regulated by the ubiquitin—proteasomal system and is present in the pathological features of parkinsonian diseases. <i>Neurobiology of Disease</i> , 2007, 27, 238-247.	2.1	32
465	Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. <i>Acta Neuropathologica</i> , 2007, 114, 5-22.	3.9	978
466	Lipid content determines aggregation of neuromelanin granules in vitro. , 2007, , 35-38.		5
467	Physiologic and Neurotoxic Properties of AÎ² Peptides. , 2007, , 179-197.		0
468	New face of neuromelanin. , 2006, , 119-123.		26

#	ARTICLE	IF	CITATIONS
469	Antigen-Epitope Retrieval To Facilitate Proteomic Analysis of Formalin-Fixed Archival Brain Tissue. <i>Analytical Chemistry</i> , 2006, 78, 7216-7221.	3.2	26
470	Anticipation of onset age in familial Parkinson's disease without SCA gene mutations. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 309-313.	1.1	3
471	Evidence for specific phases in the development of human neuromelanin. <i>Neurobiology of Aging</i> , 2006, 27, 506-512.	1.5	57
472	Differences in regional brain atrophy in genetic forms of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2006, 27, 387-393.	1.5	31
473	Inflammatory S100A9 and S100A12 proteins in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2006, 27, 1554-1563.	1.5	146
474	Neuropathology in the S305S tau gene mutation. <i>Brain</i> , 2006, 129, E40-E40.	3.7	17
475	Î²-Amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes. <i>Proteomics</i> , 2006, 6, 6566-6577.	1.3	62
476	Cognitive, Extrapyramidal, and Magnetic Resonance Imaging Predictors of Functional Impairment in Nondemented Older Community Dwellers: The Sydney Older Person Study. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 3-10.	1.3	31
477	Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2006, 154, 72-78.	1.4	56
478	Inhibition of nitric oxide and reactive oxygen species production improves the ability of a sunscreen to protect from sunburn, immunosuppression and photocarcinogenesis. <i>British Journal of Dermatology</i> , 2006, 155, 408-415.	1.4	38
479	Ubiquitin-positive inclusions and progression of pathology in frontotemporal dementia and motor neurone disease identifies a group with mainly early pathology. <i>Neuropathology and Applied Neurobiology</i> , 2006, 32, 83-91.	1.8	27
480	Comparison of extent of tau pathology in patients with frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), frontotemporal lobar degeneration with Pick bodies and early onset Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2006, 32, 374-387.	1.8	34
481	Evidence for specific phases in the development of human neuromelanin. <i>Journal of Neural Transmission</i> , 2006, 113, 721-728.	1.4	35
482	Investigation of the lipid component of neuromelanin. <i>Journal of Neural Transmission</i> , 2006, 113, 735-739.	1.4	10
483	P25Î± immunoreactive but Î±-synuclein immunonegative neuronal inclusions in multiple system atrophy. <i>Acta Neuropathologica</i> , 2006, 111, 193-195.	3.9	25
484	An immunohistochemical study of cases of sporadic and inherited frontotemporal lobar degeneration using 3R- and 4R-specific tau monoclonal antibodies. <i>Acta Neuropathologica</i> , 2006, 111, 329-340.	3.9	91
485	A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration. <i>International Journal of Geriatric Psychiatry</i> , 2006, 21, 171-179.	1.3	30
486	Comparison of motor, cognitive, and behavioral features in progressive supranuclear palsy and Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 632-638.	2.2	52

#	ARTICLE	IF	CITATIONS
487	Mutations in progranulin explain atypical phenotypes with variants in MAPT. <i>Brain</i> , 2006, 129, 3124-3126.	3.7	91
488	Progression in Frontotemporal Dementia. <i>Archives of Neurology</i> , 2006, 63, 1627.	4.9	189
489	Preserved Cognition and Functional Independence after a Large Right Posterior Cerebral Artery Infarct: Longitudinal Clinical and Neuropathological Findings. <i>Neurocase</i> , 2006, 12, 81-90.	0.2	4
490	Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson's disease. , 2006, , 99-103.		77
491	Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium. <i>Neurology</i> , 2005, 65, 1863-1872.	1.5	4,604
492	Dolichol is the major lipid component of human substantia nigra neuromelanin. <i>Journal of Neurochemistry</i> , 2005, 92, 990-995.	2.1	61
493	Differential effects of human neuromelanin and synthetic dopamine melanin on neuronal and glial cells. <i>Journal of Neurochemistry</i> , 2005, 95, 599-608.	2.1	28
494	Novel 'inflammatory plaque' pathology in presenilin-1 Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2005, 31, 503-511.	1.8	19
495	Clarifying Lewy-body parkinsonism with visual hallucinations. <i>Lancet Neurology</i> , The, 2005, 4, 588-589.	4.9	3
496	Pick bodies in a family with presenilin-1 Alzheimer's disease. <i>Annals of Neurology</i> , 2005, 57, 139-143.	2.8	60
497	GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. <i>Annals of Neurology</i> , 2005, 58, 829-839.	2.8	191
498	Staging disease severity in movement disorder tauopathies: Brain atrophy separates progressive supranuclear palsy from corticobasal degeneration. <i>Movement Disorders</i> , 2005, 20, 34-39.	2.2	22
499	Pallidal stimulation reduces treatment-induced dyskinesias in a minimal-change multiple system atrophy. <i>Movement Disorders</i> , 2005, 20, 1042-1047.	2.2	25
500	What is the dominant α^2 species in human brain tissue? A review. <i>Neurotoxicity Research</i> , 2005, 7, 29-41.	1.3	41
501	Insoluble β -synuclein in Alzheimer's disease without Lewy body formation. <i>Neurotoxicity Research</i> , 2005, 7, 69-76.	1.3	10
502	The emergence of proto-objects in complex visual hallucinations. <i>Behavioral and Brain Sciences</i> , 2005, 28, 767-768.	0.4	2
503	A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease. <i>Brain</i> , 2005, 128, 2272-2280.	3.7	100
504	The pathological basis of semantic dementia. <i>Brain</i> , 2005, 128, 1984-1995.	3.7	313

#	ARTICLE	IF	CITATIONS
505	A possible role for humoral immunity in the pathogenesis of Parkinson's disease. <i>Brain</i> , 2005, 128, 2665-2674.	3.7	307
506	Pathologically proven frontotemporal dementia presenting with severe amnesia. <i>Brain</i> , 2005, 128, 597-605.	3.7	167
507	Clinical deficits correlate with regional cerebral atrophy in progressive supranuclear palsy. <i>Brain</i> , 2005, 128, 1259-1266.	3.7	133
508	Î±-Synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. <i>Brain</i> , 2005, 128, 2654-2664.	3.7	187
509	Phosphorylation of Apolipoprotein-E at an Atypical Protein Kinase CK2 PSD/E Site in Vitro. <i>Biochemistry</i> , 2005, 44, 7346-7353.	1.2	28
510	Neuromelanin in human dopamine neurons: Comparison with peripheral melanins and relevance to Parkinson's disease. <i>Progress in Neurobiology</i> , 2005, 75, 109-124.	2.8	313
511	Localization of immunoreactivity for Deleted in Colorectal Cancer (DCC), the receptor for the guidance factor netrin-1, in ventral tier dopamine projection pathways in adult rodents. <i>Neuroscience</i> , 2005, 131, 671-681.	1.1	69
512	Distribution of brain atrophy in behavioral variant frontotemporal dementia. <i>Journal of the Neurological Sciences</i> , 2005, 232, 83-90.	0.3	78
513	Variable Phenotype of Alzheimer's Disease with Spastic Paraparesis. <i>Research and Perspectives in Alzheimer's Disease</i> , 2005, , 73-92.	0.1	1
514	Thalamic and Cortical Changes in Parkinsonian Disorders. , 2005, , 415-424.		0
515	Organization of Human Brain Stem Nuclei. , 2004, , 267-320.		21
516	Astrocytic degeneration relates to the severity of disease in frontotemporal dementia. <i>Brain</i> , 2004, 127, 2214-2220.	3.7	93
517	The Serotonin and Tachykinin Systems. , 2004, , 1205-1256.		10
518	Similar early clinical presentations in familial and non-familial frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2004, 75, 1743-1745.	0.9	25
519	Clinicopathological Staging of Frontotemporal Dementia Severity: Correlation with Regional Atrophy. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004, 17, 311-315.	0.7	83
520	Substantia Nigra and Locus Coeruleus. , 2004, , 449-463.		23
521	Are Parkinson's Disease with dementia and Dementia with Lewy Bodies the Same Entity?. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2004, 17, 137-145.	1.2	180
522	Increased Fas ligand expression by T cells and tumour cells in the progression of actinic keratosis to squamous cell carcinoma. <i>British Journal of Dermatology</i> , 2004, 151, 42-49.	1.4	18

#	ARTICLE	IF	CITATIONS
523	Dementia with Lewy bodies. <i>Lancet Neurology</i> , The, 2004, 3, 19-28.	4.9	645
524	Regional and cellular pathology in frontotemporal dementia: relationship to stage of disease in cases with and without Pick bodies. <i>Acta Neuropathologica</i> , 2004, 108, 515-523.	3.9	105
525	Frequency of tau mutations in familial and sporadic frontotemporal dementia and other tauopathies. <i>Journal of Neurology</i> , 2004, 251, 1098-104.	1.8	43
526	Identification of families with cortical Lewy body disease. <i>American Journal of Medical Genetics Part A</i> , 2004, 128B, 118-122.	2.4	13
527	Clinicopathological correlates in frontotemporal dementia. <i>Annals of Neurology</i> , 2004, 56, 399-406.	2.8	549
528	Partial lesion of thalamic ventral intermediate nucleus after chronic high-frequency stimulation. <i>Movement Disorders</i> , 2004, 19, 709-711.	2.2	11
529	Genetic contributions to Parkinson's disease. <i>Brain Research Reviews</i> , 2004, 46, 44-70.	9.1	83
530	A critical review of the development and importance of proteinaceous aggregates in animal models of Parkinson's disease: new insights into Lewy body formation. <i>Parkinsonism and Related Disorders</i> , 2004, 10, 191-202.	1.1	50
531	Positional effects of presenilin-1 mutations on tau phosphorylation in cortical plaques. <i>Neurobiology of Disease</i> , 2004, 15, 115-119.	2.1	33
532	Relationship between hippocampal volume and CA1 neuron loss in brains of humans with and without Alzheimer's disease. <i>Neuroscience Letters</i> , 2004, 361, 9-12.	1.0	53
533	Hemorrhage is uncommon in new Alzheimer family with Flemish amyloid precursor protein mutation. <i>Neurology</i> , 2004, 63, 1613-1617.	1.5	35
534	The dopamine receptor agonist lisuride attenuates iron-mediated dopaminergic neurodegeneration. <i>Experimental Neurology</i> , 2003, 184, 530-535.	2.0	31
535	Identifying severely atrophic cortical subregions in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2003, 24, 797-806.	1.5	61
536	Relationships between various behavioural abnormalities and nigrostriatal dopamine depletion in the unilateral 6-OHDA-lesioned rat. <i>Behavioural Brain Research</i> , 2003, 139, 105-113.	1.2	59
537	The left human speech-processing cortex is thinner but longer than the right. <i>Laterality</i> , 2003, 8, 247-260.	0.5	58
538	Identifying the Pattern of Olfactory Deficits in Parkinson Disease Using the Brief Smell Identification Test. <i>Archives of Neurology</i> , 2003, 60, 545.	4.9	172
539	Presenilin-1 Mutation L271V Results in Altered Exon 8 Splicing and Alzheimer's Disease with Non-cored Plaques and No Neuritic Dystrophy. <i>Journal of Biological Chemistry</i> , 2003, 278, 6748-6754.	1.6	54
540	Mutations in the tau gene that cause an increase in three repeat tau and frontotemporal dementia. <i>Brain</i> , 2003, 126, 814-826.	3.7	114

#	ARTICLE	IF	CITATIONS
541	Olfactory deficits and sleep disturbances in Parkinson's disease: a case-control survey. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003, 74, 956-958.	0.9	24
542	Genetically confirmed clinical Huntington's disease with no observable cell loss. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003, 74, 968-970.	0.9	31
543	Survival in frontotemporal dementia. <i>Neurology</i> , 2003, 61, 349-354.	1.5	355
544	Severity of gliosis in Pick's disease and frontotemporal lobar degeneration: tau-positive glia differentiate these disorders. <i>Brain</i> , 2003, 126, 827-840.	3.7	78
545	Staging disease severity in pathologically confirmed cases of frontotemporal dementia. <i>Neurology</i> , 2003, 60, 1005-1011.	1.5	247
546	A 6-Year Study of Cognition and Spatial Function in the Demented and Non-Demented Elderly: The Sydney Older Persons Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003, 16, 181-186.	0.7	14
547	Patients with vascular dementia due to microvascular pathology have significant hippocampal neuronal loss. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002, 72, 747-751.	0.9	116
548	Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. <i>Brain</i> , 2002, 125, 391-403.	3.7	587
549	Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. <i>Brain</i> , 2002, 125, 2431-2445.	3.7	383
550	Intraneuronal advanced glycation endproducts in presenilin-1 Alzheimer's disease. <i>NeuroReport</i> , 2002, 13, 601-604.	0.6	31
551	Neurofilament-Immunoreactive Neurons in Alzheimer's Disease and Dementia with Lewy Bodies. <i>Neurobiology of Disease</i> , 2002, 9, 249-257.	2.1	37
552	Pyramidal Cell Loss in Motor Cortices in Huntington's Disease. <i>Neurobiology of Disease</i> , 2002, 10, 378-386.	2.1	101
553	An inflammatory review of Parkinson's disease. <i>Progress in Neurobiology</i> , 2002, 68, 325-340.	2.8	297
554	Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. <i>Brain</i> , 2002, 125, 789-800.	3.7	126
555	Selective loss of pyramidal neurons in the pre-supplementary motor cortex in Parkinson's disease. <i>Movement Disorders</i> , 2002, 17, 1166-1173.	2.2	111
556	Postmortem analysis of bilateral subthalamic electrode implants in Parkinson's disease. <i>Movement Disorders</i> , 2002, 17, 133-137.	2.2	91
557	Comparison of the basal ganglia in rats, marmosets, macaques, baboons, and humans: Volume and neuronal number for the output, internal relay, and striatal modulating nuclei. <i>Journal of Comparative Neurology</i> , 2002, 445, 238-255.	0.9	223
558	Neuron loss from the hippocampus of Alzheimer's disease exceeds extracellular neurofibrillary tangle formation. <i>Acta Neuropathologica</i> , 2002, 103, 370-376.	3.9	159

#	ARTICLE	IF	CITATIONS
559	Consensus neuropathological diagnosis of common dementia syndromes: testing and standardising the use of multiple diagnostic criteria. <i>Acta Neuropathologica</i> , 2002, 104, 72-78.	3.9	54
560	Inflammation is associated with progression of actinic keratoses to squamous cell carcinomas in humans. <i>British Journal of Dermatology</i> , 2002, 146, 810-815.	1.4	107
561	Selective hippocampal neuron loss in dementia with Lewy bodies. <i>Annals of Neurology</i> , 2002, 51, 125-128.	2.8	53
562	Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. <i>Brain</i> , 2002, 125, 789-800.	3.7	24
563	Which Basal Ganglia Surgical Targets Ameliorate Parkinsonian Symptoms?. <i>Advances in Behavioral Biology</i> , 2002, , 533-542.	0.2	0
564	Neurofilament-Immunoreactive Neurons Are Not Selectively Vulnerable in Alzheimer's Disease. <i>Neurobiology of Disease</i> , 2001, 8, 136-146.	2.1	8
565	Relationship between DNA fragmentation, morphological changes and neuronal loss in Alzheimer's disease and dementia with Lewy bodies. <i>Acta Neuropathologica</i> , 2001, 101, 616-624.	3.9	48
566	Cortical Lewy body pathology in the diagnosis of dementia. <i>Acta Neuropathologica</i> , 2001, 102, 355-363.	3.9	262
567	Parkinson's disease with late Pick's dementia. <i>Movement Disorders</i> , 2001, 16, 311-319.	2.2	12
568	Corticobasal syndrome with tau pathology. <i>Movement Disorders</i> , 2001, 16, 656-667.	2.2	61
569	Clinical and pathological features of a parkinsonian syndrome in a family with an Ala53Thr α -synuclein mutation. <i>Annals of Neurology</i> , 2001, 49, 313-319.	2.8	364
570	Severe Anterograde Amnesia with Extensive Hippocampal Degeneration in a Case of Rapidly Progressive Frontotemporal Dementia.. <i>Neurocase</i> , 2001, 7, 57-64.	0.2	24
571	Alzheimer's disease: Its diagnosis and pathogenesis. <i>International Review of Neurobiology</i> , 2001, 48, 167-217.	0.9	17
572	Lesion of thalamic centromedian "parafascicular complex after chronic deep brain stimulation. <i>Neurology</i> , 2001, 56, 1576-1579.	1.5	51
573	Cortical degeneration associated with phonologic and semantic language impairments in AD. <i>Neurology</i> , 2001, 56, 944-950.	1.5	39
574	Transforming growth factor- β 2 produced by regressor tumors inhibits, while IL-10 produced by regressor tumors enhances, Langerhans cell migration from skin. <i>International Immunology</i> , 2001, 13, 1147-1154.	1.8	59
575	Clinical and pathological features of a parkinsonian syndrome in a family with an Ala53Thr α -synuclein mutation. , 2001, 49, 313.		6
576	Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. <i>Annals of Neurology</i> , 2001, 49, 313-9.	2.8	98

#	ARTICLE	IF	CITATIONS
577	A role for the substantia nigra pars reticulata in the gaze palsy of progressive supranuclear palsy. <i>Brain</i> , 2000, 123, 724-732.	3.7	41
578	Degeneration of the central median-parafascicular complex in Parkinson's disease. <i>Annals of Neurology</i> , 2000, 47, 345-352.	2.8	165
579	Regional brain atrophy in progressive supranuclear palsy and Lewy body disease. <i>Annals of Neurology</i> , 2000, 47, 718-728.	2.8	116
580	Topical Retinoic Acid Enhances, and a Dark Tan Protects, from Subdermal Solar-Simulated Photocarcinogenesis. <i>Journal of Investigative Dermatology</i> , 2000, 114, 923-927.	0.3	36
581	Cytokine profiles in spontaneously regressing basal cell carcinomas. <i>British Journal of Dermatology</i> , 2000, 143, 91-98.	1.4	84
582	Alzheimer's Disease And Inflammation: A Review Of Cellular And Therapeutic Mechanisms. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2000, 27, 1-8.	0.9	174
583	Practical measures to simplify the Braak tangle staging method for routine pathological screening. <i>Acta Neuropathologica</i> , 2000, 99, 199-208.	3.9	42
584	Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene. <i>Brain</i> , 2000, 123, 880-893.	3.7	277
585	Cortical Inflammation in Alzheimer Disease but Not Dementia With Lewy Bodies. <i>Archives of Neurology</i> , 2000, 57, 817.	4.9	67
586	Anti-inflammatory Drugs Protect Against Alzheimer Disease at Low Doses. <i>Archives of Neurology</i> , 2000, 57, 1586-91.	4.9	146
587	Effect of Anti-inflammatory Medications on Neuropathological Findings in Alzheimer Disease. <i>Archives of Neurology</i> , 2000, 57, 831.	4.9	69
588	Idiopathic generalized epilepsy. <i>Neurology</i> , 2000, 55, 1101-1106.	1.5	57
589	Loss of thalamic intralaminar nuclei in progressive supranuclear palsy and Parkinson's disease: clinical and therapeutic implications. <i>Brain</i> , 2000, 123, 1410-1421.	3.7	219
590	Mitochondrial ultrastructure and density in a primate model of persistent tardive dyskinesia. <i>Life Sciences</i> , 2000, 66, 1345-1350.	2.0	10
591	Degeneration of anterior thalamic nuclei differentiates alcoholics with amnesia. <i>Brain</i> , 2000, 123, 141-154.	3.7	351
592	Degeneration of the central median-parafascicular complex in Parkinson's disease. , 2000, 47, 345.		6
593	Regional brain atrophy in progressive supranuclear palsy and Lewy body disease. , 2000, 47, 718.		1
594	Regional brain atrophy in progressive supranuclear palsy and Lewy body disease. <i>Annals of Neurology</i> , 2000, 47, 718-728.	2.8	4

#	ARTICLE	IF	CITATIONS
595	Degeneration of the central median-parafascicular complex in Parkinson's disease. <i>Annals of Neurology</i> , 2000, 47, 345-52.	2.8	73
596	Specific temporoparietal gyral atrophy reflects the pattern of language dissolution in Alzheimer's disease. <i>Brain</i> , 1999, 122, 675-686.	3.7	87
597	Effect of inhibitors of oxygen radical and nitric oxide formation on UV radiation-induced erythema, immunosuppression and carcinogenesis. <i>Redox Report</i> , 1999, 4, 316-319.	1.4	18
598	The external globus pallidus in patients with Parkinson's disease and progressive supranuclear palsy. <i>Movement Disorders</i> , 1999, 14, 626-633.	2.2	35
599	Neuropathology of three clinical cases prospectively diagnosed as dementia with Lewy bodies. <i>Journal of Clinical Neuroscience</i> , 1999, 6, 149-154.	0.8	3
600	Neuronal loss in functional zones of the cerebellum of chronic alcoholics with and without Wernicke's encephalopathy. <i>Neuroscience</i> , 1999, 91, 429-438.	1.1	167
601	Brain shrinkage in alcoholics: a decade on and what have we learned?. <i>Progress in Neurobiology</i> , 1999, 58, 381-387.	2.8	172
602	The Internal Globus Pallidus Is Affected in Progressive Supranuclear Palsy and Parkinson's Disease. <i>Experimental Neurology</i> , 1999, 158, 135-142.	2.0	38
603	Clinical and Neuropathological Abnormalities in Baboons Treated with HTP, the Tetrahydropyridine Analog of Haloperidol. <i>Experimental Neurology</i> , 1999, 158, 155-163.	2.0	18
604	Sunscreens and vitamin E provide some protection to the skin immune system from solar-simulated UV radiation. <i>Australasian Journal of Dermatology</i> , 1998, 39, 71-75.	0.4	4
605	Simplified neuropathological diagnosis of dementia with Lewy bodies. <i>Neuropathology and Applied Neurobiology</i> , 1998, 24, 195-201.	1.8	38
606	Neurofibrillary degeneration and cell loss in the nucleus basalis in comparison to cortical Alzheimer pathology. <i>Neurobiology of Aging</i> , 1998, 19, 297-306.	1.5	53
607	The midbrain dopaminergic cell groups in the baboon <i>papio ursinus</i> . <i>Brain Research Bulletin</i> , 1998, 47, 611-623.	1.4	16
608	Regional Specificity of Brain Atrophy in Huntington's Disease. <i>Experimental Neurology</i> , 1998, 154, 663-672.	2.0	224
609	Variation in hippocampal neuron number with age and brain volume. <i>Cerebral Cortex</i> , 1998, 8, 710-718.	1.6	96
610	Two novel presenilin-1 mutations (Ser169Leu and Pro436Gln) associated with very early onset Alzheimer's disease. <i>NeuroReport</i> , 1998, 9, 3335-3339.	0.6	68
611	The nucleus basalis (Ch4) in the alcoholic Wernicke-Korsakoff syndrome: reduced cell number in both amnesic and non-amnesic patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1997, 63, 315-320.	0.9	41
612	Operational criteria for the classification of chronic alcoholics: identification of Wernicke's encephalopathy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1997, 62, 51-60.	0.9	373

#	ARTICLE	IF	CITATIONS
613	Utilising Molecular Biological and Histopathological Techniques to Study the Dopaminergic System in Patients with Melancholia. Australian and New Zealand Journal of Psychiatry, 1997, 31, 27-35.	1.3	7
614	Language-Associated Cortical Regions Are Proportionally Larger in the Female Brain. Archives of Neurology, 1997, 54, 171-176.	4.9	224
615	The Subthalamic Nucleus in Parkinson's Disease and Progressive Supranuclear Palsy. Journal of Neuropathology and Experimental Neurology, 1997, 56, 132-142.	0.9	60
616	Progressive Supranuclear Palsy Affects both the Substantia Nigra Pars Compacta and Reticulata. Experimental Neurology, 1997, 144, 183-192.	2.0	58
617	Specific A10 Dopaminergic Nuclei in the Midbrain Degenerate in Parkinson's Disease. Experimental Neurology, 1997, 144, 202-213.	2.0	118
618	Further evidence for an association between a mutation in the APP gene and Lewy body formation. Neuroscience Letters, 1997, 227, 49-52.	1.0	27
619	Cell loss in the nucleus basalis is related to regional cortical atrophy in Alzheimer's disease. Neuroscience, 1997, 78, 641-652.	1.1	60
620	The cerebral cortex is damaged in chronic alcoholics. Neuroscience, 1997, 79, 983-998.	1.1	474
621	Significant loss of pyramidal neurons in the angular gyrus of patients with Huntington's disease. Neuropathology and Applied Neurobiology, 1997, 23, 492-495.	1.8	50
622	Prediction of minimal erythema dose with a reflectance melanin meter. British Journal of Dermatology, 1997, 136, 714-718.	1.4	5
623	Chronic alcohol consumption does not cause hippocampal neuron loss in humans. , 1997, 7, 78-87.		148
624	Topography of brain atrophy during normal aging and alzheimer's disease. Neurobiology of Aging, 1996, 17, 513-521.	1.5	170
625	Glial fibrillary acidic protein (GFAP) immunohistochemistry in human cortex: a quantitative study using different antisera. Neuroscience Letters, 1996, 209, 29-32.	1.0	48
626	Loss of vasopressin-immunoreactive neurons in alcoholics is dose-related and time-dependent. Neuroscience, 1996, 72, 699-708.	1.1	137
627	Substantia Nigra Pars Reticulata Neurons in Parkinson's Disease. Experimental Neurology, 1996, 5, 49-55.	1.7	56
628	Improved Selectivity and Sensitivity in the Visualization of Neurofibrillary Tangles, Plaques and Neuropil Threads. Experimental Neurology, 1996, 5, 177-187.	1.7	19
629	Midbrain neuropathology in idiopathic Parkinson's disease and diffuse Lewy body disease. Journal of Clinical Neuroscience, 1996, 3, 52-60.	0.8	93
630	Quantification of cortical atrophy in a case of progressive fluent aphasia. Brain, 1996, 119, 181-190.	3.7	95

#	ARTICLE	IF	CITATIONS
631	Microwave Modification of the Methenamine Silver Technique for the Demonstration of Alzheimer-Type Pathology. <i>Journal of Histotechnology</i> , 1996, 19, 33-38.	0.2	6
632	Regional Brain Atrophy in Idiopathic Parkinson's Disease and Diffuse Lewy Body Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 1996, 7, 304-313.	0.7	30
633	Chronic alcoholism in the absence of Wernicke-Korsakoff syndrome and cirrhosis does not result in the loss of serotonergic neurons from the median raphe nucleus. <i>Metabolic Brain Disease</i> , 1996, 11, 217-227.	1.4	12
634	Anatomical and immunohistochemical identification of catecholaminergic neurones in brain slice preparations used in electrophysiology. <i>Journal of Neuroscience Methods</i> , 1996, 64, 83-93.	1.3	11
635	Diagnostic evaluation of the substantia nigra. <i>Neuropathology and Applied Neurobiology</i> , 1996, 22, 228-232.	1.8	3
636	Chronic Alcoholics without Wernicke-Korsakoff Syndrome or Cirrhosis Do Not Lose Serotonergic Neurons in the Dorsal Raphe Nucleus. <i>Alcoholism: Clinical and Experimental Research</i> , 1996, 20, 61-66.	1.4	30
637	NORADRENERGIC LOCUS COERULEUS NEURONS. <i>Alcoholism: Clinical and Experimental Research</i> , 1996, 20, 191-192.	1.4	6
638	Cytoarchitectural distribution of calcium binding proteins in midbrain dopaminergic regions of rats and humans. , 1996, 364, 121-150.		164
639	Reproducible sampling regimen for specific cortical regions: application to speech-associated areas. <i>Journal of Neuroscience Methods</i> , 1996, 67, 43-51.	1.3	22
640	Diffuse Lewy body disease: clinical features in nine cases without coexistent Alzheimer's disease.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1996, 60, 531-538.	0.9	52
641	Pattern of Midbrain Pathology in Different Parkinsonian Syndromes. <i>Advances in Behavioral Biology</i> , 1996, , 441-444.	0.2	2
642	Diagnostic evaluation of the substantia nigra. <i>Neuropathology and Applied Neurobiology</i> , 1996, 22, 228-232.	1.8	4
643	Microwave Modification of the Methenamine Silver Technique for the Demonstration of Alzheimer-Type Pathology. <i>Journal of Histotechnology</i> , 1996, 19, 33-38.	0.2	4
644	Brain stem nuclei in sudden infant death syndrome (SIDS): volumes, neuronal numbers and positions. <i>Neuropathology and Applied Neurobiology</i> , 1995, 21, 262-268.	1.8	12
645	Neurofibrillary tangles in chronic alcoholics. <i>Neuropathology and Applied Neurobiology</i> , 1995, 21, 312-318.	1.8	41
646	Spontaneous regression of human melanoma/nonmelanoma skin cancer: Association with infiltrating CD4+ T cells. <i>World Journal of Surgery</i> , 1995, 19, 352-358.	0.8	134
647	Ubiquitin-positive achromatic neurons in corticobasal degeneration. <i>Acta Neuropathologica</i> , 1995, 90, 68-75.	3.9	39
648	Comparison of the Number of Vasopressin-Producing Hypothalamic Neurons in Rats and Humans. <i>Journal of Neuroendocrinology</i> , 1995, 7, 629-636.	1.2	14

#	ARTICLE	IF	CITATIONS
649	Serotonin and alcohol-related brain damage. <i>Metabolic Brain Disease</i> , 1995, 10, 25-30.	1.4	28
650	Mechanisms of cell death in cholinergic basal forebrain neurons in chronic alcoholics. <i>Metabolic Brain Disease</i> , 1995, 10, 81-91.	1.4	34
651	Calbindin D28k-containing neurons are restricted to the medial substantia nigra in humans. <i>Neuroscience</i> , 1995, 65, 87-91.	1.1	53
652	Quantitative analysis of the variability of substantia nigra pigmented cell clusters in the human. <i>Neuroscience</i> , 1995, 68, 539-551.	1.1	54
653	Ascending Noradrenergic and Serotonergic Systems in the Human Brainstem. <i>Advances in Behavioral Biology</i> , 1995, , 155-171.	0.2	2
654	Cytoarchitecture and Chemistry of Midbrain Dopaminergic Cell Groups. <i>Advances in Behavioral Biology</i> , 1995, , 115-127.	0.2	1
655	Ubiquitin-positive achromatic neurons in corticobasal degeneration. <i>Acta Neuropathologica</i> , 1995, 90, 68-75.	3.9	8
656	Neurotransmitter Changes in Alzheimer's Disease. <i>Advances in Behavioral Biology</i> , 1995, , 199-219.	0.2	5
657	Cytoarchitecture and Chemistry of the Human Ascending Cholinergic System. <i>Advances in Behavioral Biology</i> , 1995, , 129-153.	0.2	0
658	Practical considerations for the use of the optical disector in estimating neuronal number. <i>Journal of Neuroscience Methods</i> , 1994, 51, 83-89.	1.3	82
659	Analysis of staining methods for different cortical plaques in Alzheimer's disease. <i>Acta Neuropathologica</i> , 1994, 87, 174-186.	3.9	30
660	Regression in basal cell carcinoma: an immunohistochemical analysis. <i>British Journal of Dermatology</i> , 1994, 130, 1-8.	1.4	135
661	Effect of Chronic Alcohol Consumption on the Human Locus Coeruleus. <i>Alcoholism: Clinical and Experimental Research</i> , 1994, 18, 1491-1496.	1.4	26
662	Neuropathological correlates of memory dysfunction in the Wernicke-Korsakoff syndrome. <i>Alcohol and Alcoholism Supplement</i> , 1994, 2, 245-51.	0.0	12
663	Analysis of staining methods for different cortical plaques in Alzheimer's disease. <i>Acta Neuropathologica</i> , 1994, 87, 174-186.	3.9	4
664	Quantitation and three-dimensional reconstruction of Ch4 nucleus in the human basal forebrain. <i>Synapse</i> , 1993, 15, 1-16.	0.6	45
665	Carcinogen-Treated Skin Allografts Rejected by T Lymphocytes Specific for Class I but Not Class II MHC Antigens. <i>Cellular Immunology</i> , 1993, 151, 291-299.	1.4	0
666	Thalamic vacuolation in acute Wernicke's encephalopathy. <i>Metabolic Brain Disease</i> , 1993, 8, 107-113.	1.4	9

#	ARTICLE	IF	CITATIONS
667	Parvalbumin as an anatomical marker for discrete subregions of the ambiguous complex in the rat. <i>Neuroscience Letters</i> , 1993, 160, 101-105.	1.0	77
668	Brainstem Serotonergic Neurons in Chronic Alcoholics With and Without the Memory Impairment of Korsakoff's Psychosis. <i>Journal of Neuropathology and Experimental Neurology</i> , 1993, 52, 567-579.	0.9	68
669	Protein kinase C transduces the signal for Langerhans' cell migration from the epidermis. <i>Immunology</i> , 1993, 79, 621-6.	2.0	27
670	Topical retinoic acid inhibits changes in Langerhans cell density during carcinogenesis. <i>In Vivo</i> , 1993, 7, 271-6.	0.6	3
671	Preliminary Evidence Suggesting Delayed Development in the Hypoglossal and Vagal Nuclei of SIDS Infants: A Necropsy Study. <i>Journal of Child Neurology</i> , 1992, 7, 44-49.	0.7	29
672	A Comparative Study of Avidin-Biotin-Peroxidase Complexes for the Immunohistochemical Detection of Antigens in Neural Tissue. <i>Biotechnic and Histochemistry</i> , 1992, 67, 367-371.	0.7	17
673	Application of antiphenylalanine hydroxylase antibodies to the study of the serotonergic system in the human brain. <i>Journal of Chemical Neuroanatomy</i> , 1992, 5, 311-313.	1.0	19
674	Rostrocaudal differences in morphology and neurotransmitter content of cells in the subretrofacial vasomotor nucleus. <i>Journal of the Autonomic Nervous System</i> , 1992, 38, 117-137.	1.9	35
675	The locus coeruleus and memory: a study of chronic alcoholics with and without the memory impairment of Korsakoff's psychosis. <i>Brain Research</i> , 1992, 598, 33-37.	1.1	39
676	Brain stem serotonin-synthesizing neurons in Alzheimer's disease: a clinicopathological correlation. <i>Acta Neuropathologica</i> , 1992, 84, 638-50.	3.9	95
677	Regulation of the Skin Immune System by Retinoids During Carcinogenesis. <i>Journal of Investigative Dermatology</i> , 1992, 99, S83-S86.	0.3	20
678	The dorsal, posterodorsal, and ventral tegmental nuclei: A cyto- and chemoarchitectonic study in the human. <i>Journal of Comparative Neurology</i> , 1992, 318, 117-137.	0.9	21
679	Control of Langerhans' cell density by a skin tumour-derived cytokine. <i>Immunology</i> , 1992, 77, 13-8.	2.0	31
680	Distribution, morphology and number of monoamine-synthesizing and substance P-containing neurons in the human dorsal raphe nucleus. <i>Neuroscience</i> , 1991, 42, 757-775.	1.1	202
681	A comparative analysis of neurons containing catecholamine-synthesizing enzymes and neuropeptide Y in the ventrolateral medulla of rats, guinea-pigs and cats. <i>Neuroscience</i> , 1991, 43, 531-550.	1.1	47
682	Four groups of tyrosine hydroxylase-immunoreactive neurons in the ventrolateral medulla of rats, guinea-pigs and cats identified on the basis of chemistry, topography and morphology. <i>Neuroscience</i> , 1991, 43, 551-568.	1.1	20
683	Cytoarchitecture of serotonin-synthesizing neurons in the pontine tegmentum of the human brain. <i>Synapse</i> , 1991, 7, 301-320.	0.6	84
684	SUBSTANCE P-CONTAINING NEURONS IN THE MESOPONTINE TEGMENTUM ARE SEVERELY AFFECTED IN PARKINSON'S DISEASE. <i>Brain</i> , 1991, 114, 2253-2267.	3.7	89

#	ARTICLE	IF	CITATIONS
685	Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. <i>Annals of Neurology</i> , 1990, 27, 373-385.	2.8	346
686	Cytoarchitecture of the human dorsal raphe nucleus. <i>Journal of Comparative Neurology</i> , 1990, 301, 147-161.	0.9	145
687	Substance P-containing neurons in the pontomesencephalic tegmentum of the human brain. <i>Neuroscience</i> , 1990, 39, 81-96.	1.1	41
688	Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease. <i>Brain Research</i> , 1990, 510, 104-107.	1.1	320
689	Human Homologs to Brainstem Nuclei Identified in Other Animals as Revealed by Acetylcholinesterase Activity. , 1990, , 149-202.		54
690	Catecholaminergic Neurons. , 1990, , 1023-1049.		29
691	Serotonin-like immunoreactive cells and fibres in the rat ventromedial mesencephalic tegmentum. <i>Brain Research Bulletin</i> , 1989, 22, 725-735.	1.4	41
692	Distribution of monoamine-synthesizing neurons in the human medulla oblongata. <i>Journal of Comparative Neurology</i> , 1988, 273, 301-317.	0.9	121
693	Distribution of substance P-like immunoreactive neurons in the human medulla oblongata: Co-localization with monoamine-synthesizing neurons. <i>Synapse</i> , 1988, 2, 353-370.	0.6	60
694	Tyrosine hydroxylase-containing neurons in the supraoptic and paraventricular nuclei of the adult human. <i>Brain Research</i> , 1988, 461, 75-86.	1.1	42
695	Substance P-like immunoreactive fibres in the ventromedial mesencephalic tegmentum of rat. <i>Brain Research Bulletin</i> , 1988, 21, 659-670.	1.4	10
696	The distribution of neuropeptide Y-like immunoreactive neurons in the human medulla oblongata. <i>Neuroscience</i> , 1988, 26, 179-191.	1.1	52
697	Ventral tegmental (A10) system: neurobiology. 1. Anatomy and connectivity. <i>Brain Research Reviews</i> , 1987, 12, 117-165.	9.1	873
698	Comparative anatomy of the ventromedial mesencephalic tegmentum in the rat, cat, monkey and human. <i>Journal of Comparative Neurology</i> , 1986, 252, 423-445.	0.9	133
699	Electron microscopic analysis of the mesencephalic ventromedial tegmentum in the cat. <i>Journal of Comparative Neurology</i> , 1984, 230, 393-412.	0.9	11
700	An adaptive measure of visuospatial impairment in Dementia with Lewy Bodies. <i>Movement Disorders Clinical Practice</i> , 0, , .	0.8	2